Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

FILE 'HOME' ENTERED AT 15:49:54 ON 17 NOV 2008

=> fil capp
'CAPP' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> fil cap
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'CAPLUS' ENTERED AT 15:51:55 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s muc1
L1 2906 MUC1

=> s l1(s)metal(A)chelator
1880500 METAL
936792 METALS
2276600 METAL
(METAL OR METALS)
12980 CHELATOR
7165 CHELATORS
17567 CHELATOR

```
                (CHELATOR OR CHELATORS)
L2          0 L1(S)METAL(A)CHELATOR

=> s l1(s)chelator
         12980 CHELATOR
          7165 CHELATORS
         17567 CHELATOR
                (CHELATOR OR CHELATORS)
L3          0 L1(S)CHELATOR

=> s mucl and metal chelator
          2906 MUC1
       1880500 METAL
        936792 METALS
       2276600 METAL
                (METAL OR METALS)
         12980 CHELATOR
          7165 CHELATORS
         17567 CHELATOR
                (CHELATOR OR CHELATORS)
          2058 METAL CHELATOR
                (METAL(W)CHELATOR)
L4          0 MUC1 AND METAL CHELATOR

=> s mucl and chelator
          2906 MUC1
         12980 CHELATOR
          7165 CHELATORS
         17567 CHELATOR
                (CHELATOR OR CHELATORS)
L5          7 MUC1 AND CHELATOR

=> d 1-7 ibib abs ti hit

L5   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:1233701  CAPLUS
TITLE:                   Breast tumor targeting with 99mTc-HYNIC-PR81 complex
                         as a new biologic radiopharmaceutical
AUTHOR(S):               Salouti, Mojtaba; Rajabi, Hossein; Babaei, Mohammad
                         Hossein; Rasaee, Mohammad Javad
CORPORATE SOURCE:        Department of Medical Physics, Tarbiat Modares
                         University, Tehran, Iran
SOURCE:                  Nuclear Medicine and Biology (2008), 35(7), 763-768
                         CODEN: NMBIEO; ISSN: 0969-8051
PUBLISHER:               Elsevier Inc.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   Human epithelial mucin, MUC1, is commonly overexpressed in
     adenocarcinoma that includes more than 80% of breast cancers.  The PR81 is
     a murine anti-MUC1 monoclonal antibody (MAb) that was prepared
     against the human breast cancer.  We developed an indirect method for
     labeling of this antibody with 99mTc in order to use the new preparation in
     immunoscintigraphy studies of BALB/c mice bearing breast tumors.  The
     99mTc-PR81 complex was prepared using the HYNIC as a chelator and
     tricine as a coligand.  The labeling efficiency determined by instant
     thin-layer chromatog. (ITLC) was 89.2%±4.7%, and radiocolloides
     measured by cellulose nitrate electrophoresis were 3.4%±0.9%.  The in
     vitro stability of labeled product was determined at room temperature by ITLC
and in
     human serum by gel filtration chromatog. - 88.3%±4.6% and 79.8%±5.7%
     over 24 h, resp.  The integrity of labeled MAb was checked by means of
     sodium dodecyl sulfate polyacrylamide gel electrophoresis, and no
```

significant fragmentation was seen. The results of cell binding studies showed that both labeled and unlabeled PR81 were able to compete for binding to MCF 7 cells. Biodistribution studies performed in female BALB/c mice with breast tumor xenografts at 4, 16 and 24 h after the 99mTc-HYNIC-PR81 injection demonstrated a specific localization of the compound at the site of tumors and min. accumulation in non target organs. The tumor imaging was performed in BALB/c mice with breast xenograft tumors at 4, 8, 12, 16, 20, 24, 28, 32 and 36 h after the complex injection. The tumors were visualized with high sensitivity after 8 h. The findings showed that the new radiopharmaceutical is a promising candidate for radioimmunoscintigraphy of the human breast cancer.

TI Breast tumor targeting with 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

AB Human epithelial mucin, MUC1, is commonly overexpressed in adenocarcinoma that includes more than 80% of breast cancers. The PR81 is a murine anti-MUC1 monoclonal antibody (MAb) that was prepared against the human breast cancer. We developed an indirect method for labeling of this antibody with 99mTc in order to use the new preparation in immunoscintigraphy studies of BALB/c mice bearing breast tumors. The 99mTc-PR81 complex was prepared using the HYNIC as a chelator and tricine as a coligand. The labeling efficiency determined by instant thin-layer chromatog. (ITLC) was 89.2%±4.7%, and radiocolloides measured by cellulose nitrate electrophoresis were 3.4%±0.9%. The in vitro stability of labeled product was determined at room temperature by ITLC and in human serum by gel filtration chromatog. - 88.3%±4.6% and 79.8%±5.7% over 24 h, resp. The integrity of labeled MAb was checked by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis, and no significant fragmentation was seen. The results of cell binding studies showed that both labeled and unlabeled PR81 were able to compete for binding to MCF 7 cells. Biodistribution studies performed in female BALB/c mice with breast tumor xenografts at 4, 16 and 24 h after the 99mTc-HYNIC-PR81 injection demonstrated a specific localization of the compound at the site of tumors and min. accumulation in non target organs. The tumor imaging was performed in BALB/c mice with breast xenograft tumors at 4, 8, 12, 16, 20, 24, 28, 32 and 36 h after the complex injection. The tumors were visualized with high sensitivity after 8 h. The findings showed that the new radiopharmaceutical is a promising candidate for radioimmunoscintigraphy of the human breast cancer.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1185477 CAPLUS
DOCUMENT NUMBER: 149:423733
TITLE: MHC-peptide complexes and MHC multimers for diagnosis, prognosis and therapy of cancer, allergy, immune or autoimmune disease, transplant rejection, infection and vaccine development
INVENTOR(S): Schoeller, Joergen; Pedersen, Henrik; Brix, Liselotte
PATENT ASSIGNEE(S): Dako Denmark A/S, Den.
SOURCE: PCT Int. Appl., 863pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008116468	A2	20081002	WO 2008-DK118	20080326

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DK 2007-461	A	20070326
US 2007-907217P	P	20070326
DK 2007-972	A	20070703
DK 2007-973	A	20070703
DK 2007-974	A	20070703
DK 2007-975	A	20070703
US 2007-929581P	P	20070703
US 2007-929582P	P	20070703
US 2007-929583P	P	20070703
US 2007-929586P	P	20070703

AB Novel compds. carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compds. possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC mols. are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compns. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

TI MHC-peptide complexes and MHC multimers for diagnosis, prognosis and therapy of cancer, allergy, immune or autoimmune disease, transplant rejection, infection and vaccine development

IT Mucins
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MUC1; MHC-peptide complexes and MHC multimers for diagnosis, prognosis and therapy of cancer, allergy, immune or autoimmune disease, transplant rejection, infection and vaccine development)

IT 7440-70-2, Calcium, biological studies
RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); MOA (Modifier or additive use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chelators or ionophores; MHC-peptide complexes and MHC multimers for diagnosis, prognosis and therapy of cancer, allergy, immune or autoimmune disease, transplant rejection, infection and vaccine development)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2008:667330 CAPLUS
DOCUMENT NUMBER:	149:72610
TITLE:	Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
AUTHOR(S):	Song, Emma Y.; Qu, Chang F.; Rizvi, Syed M. A.; Raja, Chand; Beretov, Julia; Morgenstern, Alfred; Apostolidis, Christos; Bruchertseifer, Frank; Perkins, Alan; Allen, Barry J.
CORPORATE SOURCE:	Centre for Experimental Radiation Oncology, Cancer

Care Centre, St. George Hospital, Kogarah, UK
SOURCE: Cancer Biology & Therapy (2008), 7(1), 76-80
CODEN: CBTAAO; ISSN: 1538-4047
PUBLISHER: Landes Bioscience
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Purpose: Control of ovarian cancer (OC) ascites remains a major objective in post-surgical treatment. The aim of this study was to investigate the effect of targeted alpha therapy (TAT) for the control of ascites in an OC ascites mouse model; the biodistribution of 213Bi-C595 and its long term toxicity. Results: MUC-1 is strongly expressed in 73% of OC tissues. At 9 days post-cell inoculation in mice, a single injection of 355 MBq/kg of 213Bi-C595 can prolong survival by 25 days. A high tumor: blood ratio (5.8) was found in biodistribution study. The maximum tolerance dose (MTD) was more than 1180 MBq/kg up to 21 wk. Methods: The expression of tumor-associated antigen mucin-1 (MUC-1) in OVCAR3 ascites cells in mice and OC cancer tissues in patients was detected by indirect immmunostaining. The monoclonal antibody (MAb) C595 was labeled with 213Bi using the chelator cDTPA to form the α-immunoconjugate (AIC). Mice were injected with different concns. of AIC by i.p administration. Changes in tumor progression were assessed by measurement of the circumference of the abdomen. Conclusions: C595 is a specific targeting vector for ovarian cancer cells, which show a high percentage of expression of MUC1. 213Bi-C595 can effectively target and kill ovarian cancer cells in vitro and in vivo. 213Bi-C595 is the recommended alpha conjugate for a Phase I clin. trial for ovarian cancer.
TI Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
AB Purpose: Control of ovarian cancer (OC) ascites remains a major objective in post-surgical treatment. The aim of this study was to investigate the effect of targeted alpha therapy (TAT) for the control of ascites in an OC ascites mouse model; the biodistribution of 213Bi-C595 and its long term toxicity. Results: MUC-1 is strongly expressed in 73% of OC tissues. At 9 days post-cell inoculation in mice, a single injection of 355 MBq/kg of 213Bi-C595 can prolong survival by 25 days. A high tumor: blood ratio (5.8) was found in biodistribution study. The maximum tolerance dose (MTD) was more than 1180 MBq/kg up to 21 wk. Methods: The expression of tumor-associated antigen mucin-1 (MUC-1) in OVCAR3 ascites cells in mice and OC cancer tissues in patients was detected by indirect immmunostaining. The monoclonal antibody (MAb) C595 was labeled with 213Bi using the chelator cDTPA to form the α-immunoconjugate (AIC). Mice were injected with different concns. of AIC by i.p administration. Changes in tumor progression were assessed by measurement of the circumference of the abdomen. Conclusions: C595 is a specific targeting vector for ovarian cancer cells, which show a high percentage of expression of MUC1. 213Bi-C595 can effectively target and kill ovarian cancer cells in vitro and in vivo. 213Bi-C595 is the recommended alpha conjugate for a Phase I clin. trial for ovarian cancer.
ST MUC1 bismuth 213 C595 anticancer radioimmunotherapy ascites ovarian cancer
IT Antitumor agents
Ascites
Dosimetry
Human
Immunoradiotherapy
Ovary, neoplasm
Pharmacokinetics
(bismuth-213 radioimmunotherapy with C595 anti-MUC1

monoclonal antibody in ovarian cancer ascites model)
IT Neoplasm
(metastasis; bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in ovarian cancer ascites model)
IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, C595, 213Bi-labeled; bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in ovarian cancer ascites model)
IT 15776-20-2D, Bi213, labeled with monoclonal antibody C595, biological studies
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in ovarian cancer ascites model)

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:663965 CAPLUS
DOCUMENT NUMBER: 147:271591
TITLE: Design and Synthesis of Mono- and Multimeric Targeted Radiopharmaceuticals Based on Novel Cyclen Ligands Coupled to Anti-MUC1 Aptamers for the Diagnostic Imaging and Targeted Radiotherapy of Cancer
AUTHOR(S): Borbas, K. Eszter; Ferreira, Catia S. M.; Perkins, Alan; Bruce, James I.; Missailidis, Sotiris
CORPORATE SOURCE: Chemistry Department, The Open University, Milton Keynes, UK
SOURCE: Bioconjugate Chemistry (2007), 18(4), 1205-1212
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:271591
AB Targeted radiopharmaceuticals offer the possibility of improved tumor imaging and radiotherapy, with reduced side effects. A variety of monoclonal antibodies and antibody fragments have previously been successfully radiolabeled and used in diagnostic imaging and targeted radiotherapy of cancer. Many such antibodies have been shown to recognize the well-characterized MUC1 tumor marker and have recently been in clin. trials. Furthermore, a number of chelators have been synthesized and are currently used as radiopharmaceuticals for imaging and therapy. We now report the synthesis of a novel, cyclen-based ligand with a sulfur-containing arm that offers increased stability of the ligand-metal complex. We have coupled this ligand with previously selected aptamers to the MUC1 tumor marker to generate a novel targeted radiopharmaceutical with improved properties. We have tested the complex against known, com. available chelators such as MAG3 in model breast cancer systems. To improve the pharmacokinetic properties of the aptamer-based targeted radiopharmaceutical, we have generated multi-aptamer complexes around a central chelator. Such multi-aptamer complexes have increased retention of the complex in circulation, without affecting the lack of immunogenicity of the complex or altering its superior tumor penetration properties.
TI Design and Synthesis of Mono- and Multimeric Targeted Radiopharmaceuticals Based on Novel Cyclen Ligands Coupled to Anti-MUC1 Aptamers for the Diagnostic Imaging and Targeted Radiotherapy of Cancer
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Design and Synthesis of Mono- and Multimeric Targeted Radiopharmaceuticals Based on Novel Cyclen Ligands Coupled to Anti-MUC1 Aptamers for the Diagnostic Imaging and Targeted Radiotherapy of Cancer

AB Targeted radiopharmaceuticals offer the possibility of improved tumor imaging and radiotherapy, with reduced side effects. A variety of monoclonal antibodies and antibody fragments have previously been successfully radiolabeled and used in diagnostic imaging and targeted radiotherapy of cancer. Many such antibodies have been shown to recognize the well-characterized MUC1 tumor marker and have recently been in clin. trials. Furthermore, a number of chelators have been synthesized and are currently used as radiopharmaceuticals for imaging and therapy. We now report the synthesis of a novel, cyclen-based ligand with a sulfur-containing arm that offers increased stability of the ligand-metal complex. We have coupled this ligand with previously selected aptamers to the MUC1 tumor marker to generate a novel targeted radiopharmaceutical with improved properties. We have tested the complex against known, com. available chelators such as MAG3 in model breast cancer systems. To improve the pharmacokinetic properties of the aptamer-based targeted radiopharmaceutical, we have generated multi-aptamer complexes around a central chelator. Such multi-aptamer complexes have increased retention of the complex in circulation, without affecting the lack of immunogenicity of the complex or altering its superior tumor penetration properties.

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT Aptamers
Imaging agents
Neoplasm
Pharmacokinetics
(preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT Diagnosis
(radiodiagnosis; preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT Radiotherapy
(targeted; preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT Imaging
(tumor; preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT 946425-20-3DP, complex with anti-MUC1 aptamers 946425-21-4DP, complex with anti-MUC1 aptamers
RL: DGN (Diagnostic use); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT 59-51-8, Methionine 79-11-8, reactions 294-90-6, Cyclen 452-95-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

IT 761411-05-6P 761411-65-8P 946148-72-7P 946425-19-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor

imaging and targeted radiotherapy)

IT 1069118-38-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of mono- and multimeric targeted radiopharmaceuticals based on cyclen ligands coupled to anti-MUC1 aptamers for tumor imaging and targeted radiotherapy)

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:480431 CAPLUS
DOCUMENT NUMBER: 146:137639
TITLE: In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A''-C595
AUTHOR(S): Qu, Chang F.; Song, Yan J.; Rizvi, Syed M. A.; Li, Yong; Smith, Ross; Perkins, Alan C.; Morgenstern, Alfred; Brechbiel, Martin; Allen, Barry J.
CORPORATE SOURCE: Centre for Experimental Radiation Oncology; Cancer Care Centre, St. George Hospital, New South Wales, Australia
SOURCE: Cancer Biology & Therapy (2005), 4(8), 848-853
CODEN: CBTAAO; ISSN: 1538-4047
PUBLISHER: Landes Bioscience
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to investigate the effect of targeted alpha therapy for the control of in vitro pancreatic cancer cell clusters and micrometastatic cancer lesions in vivo. The expression of tumor-associated antigen MUC-1 on 3 pancreatic cancer cell clusters and animal xenografts was detected by indirect immmunostaining. Monoclonal antibodies C595 (test) and A2 (non-specific control) were labeled with 213Bi using the chelator CHX.A'' to form the alpha-immunoconjugate (AIC). Cell clusters were incubated with AIC and examined at 48 h. Apoptosis was documented using the TUNEL assay. In vivo, an antiproliferative effect for tumors was tested at two days post-s.c. cell inoculation. Mice were injected with different concns. of AIC by regional or systemic administration. Changes in tumor progression were assessed by tumor size. MUC-1 is strongly expressed on CFPAC-1, PANC-1 and moderate expression was found CAPAN-1 cell clusters and tumor xenografts. The AICs can target and kill cancer cell clusters (100 mm) in vitro. Some 73-81 % of cells were TUNEL pos. cells in the clusters after incubation with AIC. At 2 days post-cell inoculation in mice, a single local injection of 74 and 148 MBq/kg of AIC causes complete inhibition of tumor growth. Systemic injections of 111, 222 and 333 MBq/kg of AIC cause significant tumor growth delay after 16 wk, compared with the nonspecific control providing 333 MBq/kg after 16 wk. CFPAC-1, PANC-1 and CAPAN-1 pancreatic cancer cell clusters and pancreatic tumor xenografts show high expression of the MUC-1 target antigen. 213Bi-C595 can specifically target and regress pancreatic cancer cell clusters in vitro, and delay and inhibit tumor growth in vivo. 213Bi-C595 may be a useful agent for the treatment of micrometastatic pancreatic cancer with overexpression of MUC1 antigen in post-surgical patients with minimal residual disease.
TI In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A''-C595
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB The aim of this study was to investigate the effect of targeted alpha therapy for the control of in vitro pancreatic cancer cell clusters and micrometastatic cancer lesions in vivo. The expression of tumor-associated antigen MUC-1 on 3 pancreatic cancer cell clusters and animal xenografts was detected by indirect immmunostaining. Monoclonal antibodies C595 (test) and A2 (non-specific control) were labeled with 213Bi using the chelator CHX.A'' to form the alpha-immunoconjugate (AIC). Cell

clusters were incubated with AIC and examined at 48 h. Apoptosis was documented using the TUNEL assay. In vivo, an antiproliferative effect for tumors was tested at two days post-s.c. cell inoculation. Mice were injected with different concns. of AIC by regional or systemic administration. Changes in tumor progression were assessed by tumor size. MUC-1 is strongly expressed on CFPAC-1, PANC-1 and moderate expression was found CAPAN-1 cell clusters and tumor xenografts. The AICs can target and kill cancer cell clusters (100 mm) in vitro. Some 73-81 % of cells were TUNEL pos. cells in the clusters after incubation with AIC. At 2 days post-cell inoculation in mice, a single local injection of 74 and 148 MBq/kg of AIC causes complete inhibition of tumor growth. Systemic injections of 111, 222 and 333 MBq/kg of AIC cause significant tumor growth delay after 16 wk, compared with the nonspecific control providing 333 MBq/kg after 16 wk. CFPAC-1, PANC-1 and CAPAN-1 pancreatic cancer cell clusters and pancreatic tumor xenografts show high expression of the MUC-1 target antigen. 213Bi-C595 can specifically target and regress pancreatic cancer cell clusters in vitro, and delay and inhibit tumor growth in vivo. 213Bi-C595 may be a useful agent for the treatment of micrometastatic pancreatic cancer with overexpression of MUC1 antigen in post-surgical patients with minimal residual disease.

ST bismuth 213 monoclonal antibody MUC1 antitumor; C595 bismuth 213 pancreas cancer micrometastasis

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:98817 CAPLUS
DOCUMENT NUMBER: 142:183318
TITLE: D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis
INVENTOR(S): McBride, William J.; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 62 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050025709	A1	20050203	US 2004-866180	20040614
US 7172751	B2	20070206		
AU 2004268932	A1	20050310	AU 2004-268932	20040614
CA 2529027	A1	20050310	CA 2004-2529027	20040614
WO 2005021494	A2	20050310	WO 2004-US18646	20040614
WO 2005021494	A9	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633773	A2	20060315	EP 2004-776484	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2008504214	T	20080214	JP 2006-533737	20040614
IN 2006CN00125	A	20070629	IN 2006-CN125	20060110
IN 2006CN00128	A	20070629	IN 2006-CN128	20060110

US 20070142296 A1 20070621 US 2006-640557 20061218
PRIORITY APPLN. INFO.: US 2003-478403P P 20030613
US 2004-866180 A1 20040614
WO 2004-US18646 W 20040614

OTHER SOURCE(S): MARPAT 142:183318

AB The present invention provides compds. of the formula X-R1-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1 (X)-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. Multi-specific antibodies against a targetable construct are used that are capable of carrying one or more diagnostic or therapeutic agents. By using this approach the characteristics of the chelator, metal chelate complex, therapeutic agent or diagnostic agent can be varied to accommodate differing applications, without raising new multi-specific antibodies. The present invention also provides methods of using these compds. in radioimmunotherapy and radiol. diagnosis and kits containing the compds.

TI D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention provides compds. of the formula X-R1-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1 (X)-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. Multi-specific antibodies against a targetable construct are used that are capable of carrying one or more diagnostic or therapeutic agents. By using this approach the characteristics of the chelator, metal chelate complex, therapeutic agent or diagnostic agent can be varied to accommodate differing applications, without raising new multi-specific antibodies. The present invention also provides methods of using these compds. in radioimmunotherapy and radiol. diagnosis and kits containing the compds.

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; labeled D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis)

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:565117 CAPLUS
DOCUMENT NUMBER: 141:122334
TITLE: Immunotherapy of B cell malignancies and autoimmune disease using unconjugated and conjugated antibodies, fragments or fusion proteins
INVENTOR(S): Goldenberg, David M.; Hansen, Hans
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; Mccall, John Douglas

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058298	A1	20040715	WO 2003-GB5700	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040219156	A1	20041104	US 2003-747199	20031230
CA 2512188	A1	20040715	CA 2003-2512188	20031231
AU 2003295166	A1	20040722	AU 2003-295166	20031231
EP 1578440	A1	20050928	EP 2003-786167	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017898	A	20051206	BR 2003-17898	20031231
CN 1756561	A	20060405	CN 2003-80110054	20031231
JP 2006513203	T	20060420	JP 2004-563380	20031231
RU 2335297	C2	20081010	RU 2005-124281	20031231
MX 2005PA07245	A	20050912	MX 2005-PA7245	20050630
IN 2005CN01727	A	20070706	IN 2005-CN1727	20050728

PRIORITY APPLN. INFO.:

US 2002-437145P	P	20021231
WO 2003-GB5700	W	20031231

AB The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed. The target antigen of the unconjugated and conjugated antibody is CD3, CD4, CD5, CD8, CD11c, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD74, CD80, CD126, MUC1 , tenascin, Ia, HMI.24, HLA-DR and tumor antigen. The antibody is human, murine, chimeric, primatized or humanized antibody. The antibody is conjugated with therapeutic agent selected from drug, toxin, immunomodulator, chelator, boron compound, photoactive agent or radionuclide.

TI Immunotherapy of B cell malignancies and autoimmune disease using unconjugated and conjugated antibodies, fragments or fusion proteins

AB The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed. The target antigen of the unconjugated and conjugated antibody is CD3, CD4, CD5, CD8, CD11c, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD74, CD80, CD126, MUC1 , tenascin, Ia, HMI.24, HLA-DR and tumor antigen. The antibody is human, murine, chimeric, primatized or humanized antibody. The antibody is conjugated with therapeutic agent selected from drug, toxin,

immunomodulator, chelator, boron compound, photoactive agent or radionuclide.

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

```
=> s muc1 and (pry<2005)
         2906 MUC1
      4592070 PRY<2005
L6          484 MUC1 AND (PRY<2005)

=> s l6 and metal
      1880500 METAL
       936792 METALS
      2276600 METAL
                (METAL OR METALS)
L7           29 L6 AND METAL

=> d l ibib abs ti hit

L7   ANSWER 1 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:490349  CAPLUS
DOCUMENT NUMBER:          148:441008
TITLE:                    One-step epigenetic switch cancer model and methods of
                          diagnosis and therapy targeted against cancer stem
                          line
INVENTOR(S):              Bergstein, Ivan
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S., 43pp., Cont.-in-part of U.S. Ser. No. 933,330.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
     US 7361336           B1    20080422    US 1999-468286          19991220 <--
     US 6004528           A     19991221    US 1997-933330          19970918
     US 20060083682       A1    20060420    US 2005-271381          20051110 <--
     US 20070036800       A1    20070215    US 2006-583744          20061018 <--
     US 20070036801       A1    20070215    US 2006-583841          20061018 <--
     US 20070036802       A1    20070215    US 2006-583857          20061018 <--
     US 7427400           B2    20080923
     US 20070036803       A1    20070215    US 2006-583860          20061018 <--
     US 20070036804       A1    20070215    US 2006-583871          20061018 <--
     US 20070041984       A1    20070222    US 2006-583859          20061018 <--
PRIORITY APPLN. INFO.:                       US 1997-933330      A2 19970918 <--
                                             US 1999-468286      A1 19991220 <--
```

AB The present invention provides novel methods for the treatment and detection of cancer which follow from the OSES model of carcinogenesis. In brief, the OSES model concludes that a clandestine relatively mutationally-spared immortal founder line (i.e., cancer stem line) exists within tumors and is responsible for fueling tumor immortality. Since the cancer stem line is directly derived from normal stem cells, the cancer stem line (like a normal stem cell) is slow-growing and non-mutant and (like a normal stem cell) rears a transit population of highly proliferative progeny cells (which may be mutant in the case of cancer

stem line progeny). Such highly proliferative and largely mortal cancer stem line progeny make up the bulk of the resulting tumor mass (in an analogous manner to which proliferative mortal progeny of normal stem cells make up the bulk of a normal developing tissue). Essentially, while conventional cancer models invoke the presence of highly proliferative mutant cancers (hypothesized to be produced by stepwise neo-Darwinian mutation-selection), they have been largely unaware of the OSES-iw proposed presence of an underlying slow-growing relatively mutationally-spared immortal cancer stem line that rears such proliferative mutant cells as its mortal progeny. Moreover, this deficiency by conventional models explains many of the inadequacies of treatment regimens derived thereof, e.g., conventional chemotherapies, irradiation, exptl. immunotherapies, as well as newer gene-directed therapies designed for treatment of cancer. In general, such conventionally-based methods attempt to eradicate fast-growing mutant cancer cells. This idea has clin. utility as, if successful, such methods may destroy the highly proliferative mutant progeny of the cancer stem line and thereby diminish tumor burden (since mortal cancer stem line progeny make up the bulk of the tumor mass), thus potentially effecting clin. remission (due to significant decrease in tumor cell burden). However, a problem associated with such treatments is that the targeted highly proliferative mutant cancer cells are largely mortal while their immortal progenitor, i.e., the cancer stem line, will remain spared of such therapies. This is disadvantageous as the cancer stem line over time can rear more highly proliferative mutant cancer cells, thereby effecting an increase in tumor cell burden and clin. relapse. By contrast, the subject invention provides novel therapies which eradicate the slow-growing relatively mutationally-spared cancer stem line which is the progenitor of the larger population of highly proliferative, largely mortal, often mutant cancer cells. Therefore, the present invention may provide a true cancer cure as it would eradicate the founder line there by alleviating and potentially preventing clin. relapse. It is a more specific object of the invention to provide a method of cancer therapy which targets slow growing, relatively mutationally-spared sym. dividing stem cells (i.e., a cancer stem line) which is the immortal founder line that rears those (largely mortal) highly proliferative mutant cancer cells normally targeted by conventional therapies. It is another specific object of the invention to provide novel and improved cancer therapies which eradicate a cancer stem line thereby destroying the immortal portion of the tumor (i.e., the cancer stem line) and in doing so providing a true cure by preventing clin. relapse. It is a more specific object of the invention to provide cancer therapies which target antigens present on the cancer stem line for the purpose of destroying the cancer stem line. It is another specific object of the invention to provide a novel method of cancer therapy which induces, in a cancer stem line, a permanent switch from sym. to asym. mitosis. It is still another specific object of the invention to provide a novel method of cancer therapy which induces, in a cancer stem line, terminal differentiation and/or programmed cell death. It is still another specific object of the invention to spare normal stem cells of significant OSES-based therapy-induced toxicities.

TI One-step epigenetic switch cancer model and methods of diagnosis and therapy targeted against cancer stem line

REFERENCE COUNT: 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI US 1997-933330 A2 19970918 <--
US 1999-468286 A1 19991220 <--

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1, therapeutic agent containing ligand specifically binding to cancer stem line-specific; one-step epigenetic switch cancer model and methods of diagnosis and therapy targeted against cancer stem line)

IT Heavy metals
Taxanes
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytoskeletal inhibitor, as therapeutic agent; one-step epigenetic switch cancer model and methods of diagnosis and therapy targeted against cancer stem line)

=> d 2-10 ibib abs ti hit

L7 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:755415 CAPLUS
DOCUMENT NUMBER: 147:173616
TITLE: Magnetic nanoparticle compositions and therapeutic methods
INVENTOR(S): Ivkov, Robert
PATENT ASSIGNEE(S): Triton Biosystems, Inc., USA
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007079276	A2	20070712	WO 2006-US60419	20061101
WO 2007079276	A3	20080221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20030032995	A1	20030213	US 2002-200082	20020719 <--
JP 2005523736	T	20050811	JP 2003-526485	20020725 <--
US 20060142748	A1	20060629	US 2005-258598	20051025 <--
US 20060142749	A1	20060629	US 2005-264680	20051101 <--
US 20070112339	A9	20070517		
CA 2628106	A1	20070712	CA 2006-2628106	20061101
EP 1945159	A2	20080723	EP 2006-849146	20061101
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:			
US 2005-264680	A	20051101	
US 2005-732368P	P	20051101	
US 2001-307785P	P	20010725	<--
US 2002-176950	A	20020618	<--
US 2002-200082	A	20020719	<--
WO 2002-US23650	W	20020725	<--
US 2003-360561	A2	20030206	<--
WO 2006-US60419	W	20061101	

AB Disclosed are thermo-therapeutic compns. for treating disease material, and methods of targeted therapy utilizing such compns. These compns. comprise stable single domain magnetic particles; magnetic nanoparticles

comprising aggregates of superparamagnetic grains; or magnetic nanoparticles comprising aggregates of stable single magnetic domain crystals and superparamagnetic grains. These compns. may also comprise a radioisotope, potential radioactive isotope, chemotherapeutic agent. These methods comprise the administration to a patient's body, body part, body fluid, or tissue of bioprobes (energy susceptive materials attached to a target-specific ligand), and the application of energy to the bioprobes so as to destroy, rupture, or inactivate the target in the patient. Energy forms, such as AMF, are utilized to provide the energy. The disclosed methods may be useful in the treatment of a variety of indications, including cancers, diseases of the immune system, central nervous system and vascular system, and pathogen-borne diseases.

TI Magnetic nanoparticle compositions and therapeutic methods

PRAI	US 2005-264680	A	20051101	
	US 2005-732368P	P	20051101	
	US 2001-307785P	P	20010725	<--
	US 2002-176950	A	20020618	<--
	US 2002-200082	A	20020719	<--
	WO 2002-US23650	W	20020725	<--
	US 2003-360561	A2	20030206	<--
	WO 2006-US60419	W	20061101	

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1; magnetic nanoparticle compns. and therapeutic methods)

IT Rare earth metals, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (magnetic nanoparticle compns. and therapeutic methods)

L7 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:175142 CAPLUS
DOCUMENT NUMBER: 146:244322
TITLE: Novel methods of cancer diagnosis and therapy targeted against a cancer stem line
INVENTOR(S): Bergstein, Ivan
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46pp., Cont. of U.S. Ser. No. 468,286.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070036800	A1	20070215	US 2006-583744	20061018 <--
US 6004528	A	19991221	US 1997-933330	19970918
US 7361336	B1	20080422	US 1999-468286	19991220 <--
PRIORITY APPLN. INFO.:			US 1997-933330	A2 19970918 <--
			US 1999-468286	A1 19991220 <--

AB Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clin. relapse after treatment.

TI Novel methods of cancer diagnosis and therapy targeted against a cancer stem line

PRAI	US 1997-933330	A2	19970918	<--
	US 1999-468286	A1	19991220	<--

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1, therapeutic agent containing ligand specifically binding

to cancer stem line-specific; cancer therapy targeting cancer stem line in tumor)

IT Heavy metals
Taxanes
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytoskeletal inhibitor, as therapeutic agent; cancer therapy targeting cancer stem line in tumor)

L7 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:268531 CAPLUS
DOCUMENT NUMBER: 144:331698
TITLE: Combinatorial Synthesis of MUC1 Glycopeptides via Polymer Blotting
INVENTOR(S): Nishimura, Shinichiro; Hinou, Hiroshi; Fumoto, Masataka
PATENT ASSIGNEE(S): National Institute of Advanced Industrial Science and Technology, Japan; Shionogi & Co., Ltd.
SOURCE: PCT Int. Appl., 713 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030840	A1	20060323	WO 2005-JP16975	20050914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1801118	A1	20070627	EP 2005-783456	20050914 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.:		
JP 2004-267521	A	20040914 <--
JP 2005-90182	A	20050325
WO 2005-JP16975	W	20050914

OTHER SOURCE(S): MARPAT 144:331698

AB The invention aims at providing novel compds. useful as platform in producing mucin-type glycopeptides which are useful in a wide field including materials for biochem. research, drugs, and food and the production of which was difficult in the prior art; and a process for the production of glycopeptides by using the platform. The aim is attained by providing novel glycopeptide derivs. X-C(=O)-(CH2)n-A1-A2-A3 (I; X = C1~C20 alkyl, C8~C30 aryl, chromophore; n = 0~20; A1 = (CH2)n CO, (CH2CH2O)1~10, oligo or polyacrylamide with d.p. 1~10, oligo or polypeptide with d.p. 1~10, O, NH; A2 = an amino acid residue cleavable with a protease; A3 = glycoamino acid residue substantially free from a protease-cleavable moiety or a glycopeptide residue which is free from a protease-cleavable moiety and contains an arbitrary glycoamino acid) bearing an aldehyde or ketone group at the end and containing an amino acid residue cleavable with a protease; and an easy and simple process for the production of glycopeptides by using the derivative as the platform. Also provided are compds. obtained by reacting I

with solid phase support containing a functional group selected from optionally protected aminooxy, hydrazide, azide, thiosemicarbazide, 1,2-diol group, or cysteine residue. The chemoselective polymer blotting method allows for rapid and efficient synthesis of glycopeptides based on a "catch and release" strategy between solid-phase and water-soluble polymer supports. The authors have developed a heterobifunctional linker sensitive to Bacillus licheniformis glutamic acid specific protease (BLase). The general procedure consists of five steps, namely (i) the solid-phase synthesis of glycopeptide containing BLase-sensitive linker, (ii) subsequent deprotections and the release of the glycopeptide from the resin, (iii) chemoselective blotting of the glycopeptide intermediates in the presence of water-soluble polymers with oxylamino functional groups, (iv) sugar elongations using glycosyltransferases, and (v) the release of target glycopeptides from the polymer platform by selective BLase promoted hydrolysis. The combined use of the solid-phase chemical syntheses of peptides and the enzymic syntheses of carbohydrates on water-soluble polymers would greatly contribute to the production of complicated glycopeptide libraries, thereby enhancing applicative research. Here, the authors report a high-throughput synthetic system for the various types of MUC1 glycopeptides exhibiting a variety of sugar moieties. The authors believe that this concept will become part of the entrenched repertoire for the synthesis of biol. important glycopeptides on the basis of glycosyltransferase reactions in automated and combinatorial syntheses.

TI Combinatorial Synthesis of MUC1 Glycopeptides via Polymer Blotting

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Combinatorial Synthesis of MUC1 Glycopeptides via Polymer Blotting

PRAI JP 2004-267521 A 20040914 <--
JP 2005-90182 A 20050325
WO 2005-JP16975 W 20050914

AB The invention aims at providing novel compds. useful as platform in producing mucin-type glycopeptides which are useful in a wide field including materials for biochem. research, drugs, and food and the production of which was difficult in the prior art; and a process for the production of glycopeptides by using the platform. The aim is attained by providing novel glycopeptide derivs. X-C(=O)-(CH2)n-A1-A2-A3 (I; X = C1~C20 alkyl, C8~C30 aryl, chromophore; n = 0~20; A1 = (CH2)n CO, (CH2CH2O)1~10, oligo or polyacrylamide with d.p. 1~10, oligo or polypeptide with d.p. 1~10, O, NH; A2 = an amino acid residue cleavable with a protease; A3 = glycoamino acid residue substantially free from a protease-cleavable moiety or a glycopeptide residue which is free from a protease-cleavable moiety and contains an arbitrary glycoamino acid) bearing an aldehyde or ketone group at the end and containing an amino acid residue cleavable with a protease; and an easy and simple process for the production of glycopeptides by using the derivative as the platform. Also provided are compds. obtained by reacting I with solid phase support containing a functional group selected from optionally protected aminooxy, hydrazide, azide, thiosemicarbazide, 1,2-diol group, or cysteine residue. The chemoselective polymer blotting method allows for rapid and efficient synthesis of glycopeptides based on a "catch and release" strategy between solid-phase and water-soluble polymer supports. The authors have developed a heterobifunctional linker sensitive to Bacillus licheniformis glutamic acid specific protease (BLase). The general procedure consists of five steps, namely (i) the solid-phase synthesis of glycopeptide containing BLase-sensitive linker, (ii) subsequent deprotections and the release of the glycopeptide from the resin, (iii) chemoselective blotting of the glycopeptide intermediates in the presence of water-soluble polymers with oxylamino functional groups, (iv) sugar elongations using glycosyltransferases, and (v) the release of target glycopeptides from the polymer platform by selective BLase promoted hydrolysis. The combined use of the solid-phase chemical syntheses of

peptides and the enzymic syntheses of carbohydrates on water-soluble polymers would greatly contribute to the production of complicated glycopeptide libraries, thereby enhancing applicative research. Here, the authors report a high-throughput synthetic system for the various types of MUC1 glycopeptides exhibiting a variety of sugar moieties. The authors believe that this concept will become part of the entrenched repertoire for the synthesis of biol. important glycopeptides on the basis of glycosyltransferase reactions in automated and combinatorial syntheses.

ST mucin peptide muc1 glycopeptide combinatorial solid phase synthesis; MUC1 glycopeptide combinatorial solid phase synthesis; glycopeptide prepn BLase sensitive linker enzymic glycosylation

IT Glycols, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(1,2-, group, reacting the compds. of formula (I) with solid phase support containing; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Mucins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MUC1, glycopeptides containing sequence of; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Functional groups
(azido group, reacting the compds. of formula (I) with solid phase support containing; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Spheres
(beads, magnetic, solid phase support of; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Polymers, uses
RL: TEM (Technical or engineered material use); USES (Uses)
(co-, solid phase support of; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Protein sequences
Solid phase synthesis supports
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Glycopeptides
RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Solid phase synthesis
(combinatorial; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Glycosylation
(enzymic; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Bacillus licheniformis
(glutamic acid specific protease (BLase); combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Functional groups
(hydrazino group, reacting the compds. of formula (I) with solid phase support containing; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Oligopeptides
RL: BCP (Biochemical process); BIOL (Biological study); PROC (Process)
(linker, cleavage by glutamic acid specific protease (BLase); combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Metals, uses
Polyethers, uses
Polymers, uses
Resins

RL: TEM (Technical or engineered material use); USES (Uses)
(solid phase support of; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Combinatorial chemistry
(solid-phase; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Functional groups
(thiosemicarbazide, reacting the compds. of formula (I) with solid phase support containing; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT Enzymes, uses
RL: CAT (Catalyst use); USES (Uses)
(α2,3-(O)-Sialyltransferase; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 122148-68-9 126392-01-6 126829-75-2 129437-45-2 133745-77-4
143249-80-3 149205-74-3 158092-75-2 164533-33-9 166526-16-5
178888-17-0 210353-30-3 210353-32-5 215805-48-4 220434-62-8
220434-63-9 264134-78-3 326595-12-4 394211-86-0 459797-54-7
609342-10-1 870259-06-6 880265-74-7 880265-76-9 880265-79-2
880265-81-6 880265-83-8 880265-85-0 880265-91-8 880265-93-0
880265-95-2 880265-97-4 880265-99-6 880266-01-3 880266-03-5
880266-05-7 880266-07-9 880266-09-1 880266-10-4 880266-12-6
880266-13-7 880266-14-8 880266-15-9 880266-16-0 880266-17-1
880266-18-2 880266-19-3 880266-20-6 880266-21-7 880266-22-8
880266-23-9 880266-24-0 880266-25-1 880266-26-2 880266-27-3
880266-28-4 880266-29-5 880266-30-8 880266-31-9 880266-32-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 56-86-0, L-Glutamic acid, processes
RL: BCP (Biochemical process); BIOL (Biological study); PROC (Process)
(cleavage by glutamic acid specific protease (BLase); combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 880101-38-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-42-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-43-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-44-0P 880101-45-1P 880101-46-2P 880101-47-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-48-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-49-5P 880101-51-9P 880101-52-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-53-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-54-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-55-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-56-4P 880101-57-5P 880101-58-6P 880101-60-0P 880101-61-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-62-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-63-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-64-4P 880101-65-5P 880101-66-6P 880101-68-8P 880101-69-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-70-2P 880101-71-3P 880101-74-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-75-7P 880101-76-8P 880101-79-1DP, immobilized on amino resion 880101-80-4DP, immobilized on amino resion 880101-81-5DP, immobilized on amino resion 880101-82-6DP, immobilized on amino resion 880101-83-7P 880101-91-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-92-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-93-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-94-0DP, conjugates

with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-95-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-96-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-97-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-98-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-99-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-00-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-02-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-03-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-04-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-05-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-06-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-07-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-08-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-09-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-10-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-11-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-12-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-13-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-14-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-16-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-17-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-19-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-21-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-23-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-25-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-27-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-30-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-31-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-32-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-33-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-75-0P 880102-87-4P 880103-07-1P 880103-13-9P 880103-21-9P 880135-72-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880135-86-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880135-88-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880135-89-7P 880135-94-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880135-95-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880136-68-5P 880136-69-6P 880136-70-9P 880136-71-0P 880136-72-1P 880136-77-6P 880136-78-7P 880136-79-8P 880136-80-1P 880136-84-5P 880136-85-6P 880136-86-7P 880137-07-5P 880137-09-7P 880137-10-0P 880137-11-1P 880137-12-2P 880137-14-4P 880137-17-7P 880137-18-8P 880137-22-4P 880137-33-7P 880137-34-8P 880137-38-2P 880137-39-3P 880137-40-6P 880137-56-4P 880137-69-9P 880137-78-0P 880137-89-3P 880137-92-8P 880137-94-0P 880138-01-2P 880138-09-0P 880138-10-3P 880138-13-6P 880138-18-1P 880138-29-4P 880138-30-7P 880138-31-8P 880138-32-9P 880138-42-1P 880138-43-2P 880138-44-3P 880138-45-4P 880138-48-7P 880138-55-6P 880138-56-7P 880138-58-9P 880138-59-0P 880138-62-5P 880138-73-8P 880138-74-9P 880138-76-1P 880138-77-2P 880138-83-0P 880138-84-1P 880138-86-3P 880138-98-7P 880139-24-2P 880140-18-1P 880140-19-2P 880140-20-5P 880140-21-6P 880140-22-7P 880140-27-2P 880140-28-3P 880140-29-4P 880140-30-7P 880140-33-0P 880140-69-2P 880140-78-3P 880140-79-4P 880140-80-7P 880140-81-8P
RL: BCP (Biochemical process); BPN (Biosynthetic preparation); BIOL

(Biological study); PREP (Preparation); PROC (Process)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 865283-68-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-75-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-76-7DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-77-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-78-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-79-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 865283-80-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 878483-11-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-28-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-30-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-32-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-34-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-36-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-73-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880101-78-0DP, immobilized on amino resion 880102-38-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-39-6DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-40-9DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-41-0DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-42-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-43-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-44-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-45-4DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-49-8DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-50-1DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-51-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-52-3DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880102-54-5P 880102-57-8P 880102-59-0P 880136-00-5DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880136-23-2DP, conjugates with poly(acrylamide-N-(6-aminooxyhexyl)acrylamide) 880136-46-9P 880136-54-9P 880136-56-1P 880136-59-4P 880136-61-8P 880136-64-1P 880136-67-4P
RL: BCP (Biochemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 865283-69-8P 865283-70-1P 865283-71-2P 865283-72-3P 865283-73-4P 865283-74-5P 865283-81-4P 865283-82-5P 865283-83-6P 865283-84-7P 865283-85-8P 865283-86-9P 865283-87-0P 865283-88-1P 865283-89-2P 865283-90-5P 865283-91-6P 865283-92-7P 865283-93-8P 865283-94-9P 865283-96-1P 865283-97-2P 865283-98-3P 865283-99-4P 865284-00-0P 865284-01-1P 865284-02-2P 865284-03-3P 865284-04-4P 865284-05-5P 865284-06-6P 865284-07-7P 865284-08-8P 865284-09-9P 865284-10-2P 865284-11-3P 865284-12-4P 865284-13-5P 865284-14-6P 865284-15-7P 865284-16-8P 880101-38-2P 880101-39-3P 880101-40-6P 880101-41-7P 880101-50-8P 880101-59-7P 880101-67-7P 880101-77-9P 880101-84-8P 880102-01-2P 880102-70-5P 880102-71-6P 880102-73-8P 880102-77-2P 880102-79-4P 880102-81-8P 880102-83-0P 880102-84-1P 880102-88-5P 880102-89-6P 880102-90-9P 880102-91-0P 880102-92-1P 880102-93-2P 880102-94-3P 880102-95-4P 880102-96-5P 880102-97-6P 880102-98-7P 880102-99-8P 880103-00-4P 880103-01-5P 880103-02-6P 880103-03-7P 880103-04-8P 880103-05-9P 880103-06-0P 880103-08-2P 880103-09-3P

880103-10-6P 880103-11-7P 880103-12-8P 880103-14-0P 880103-15-1P
880103-16-2P 880103-17-3P 880103-18-4P 880103-19-5P 880103-20-8P
880103-22-0P 880103-23-1P 880103-24-2P 880103-25-3P 880103-26-4P
880103-27-5P 880103-28-6P 880103-29-7P 880103-30-0P 880103-31-1P
880103-32-2P 880103-33-3P 880103-34-4P 880103-35-5P 880103-36-6P
880103-42-4P 880103-43-5P 880103-44-6P 880103-45-7P 880103-46-8P
880103-47-9P 880103-48-0P 880104-61-0P 880135-90-0P 880136-73-2P
880136-74-3P 880136-76-5P 880136-81-2P 880137-08-6P 880137-15-5P
880137-16-6P 880137-35-9P 880137-36-0P 880137-37-1P 880137-70-2P
880137-71-3P 880138-06-7P 880138-07-8P 880138-08-9P 880138-27-2P
880138-37-4P 880138-50-1P 880138-51-2P 880138-52-3P 880138-53-4P
880138-60-3P 880138-61-4P 880138-81-8P 880138-82-9P 880139-51-5P
880139-74-2P 880139-81-1P 880140-06-7P 880140-23-8P 880140-24-9P
880140-25-0P 880140-26-1P 880140-52-3P 880140-53-4P 880140-54-5P
880140-55-6P 880140-82-9P 880140-83-0P 880140-84-1P 880140-99-8P
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 880103-41-3P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 37237-43-7, β1,4-Galactosyl transferase 77537-85-0, α2,3-Sialyl transferase
RL: CAT (Catalyst use); USES (Uses)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 42989-85-5 869563-91-7D, conjugates with glycopeptides
RL: RCT (Reactant); RACT (Reactant or reagent)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 645-88-5DP, reaction products with amino resin 865283-66-5P
865283-68-7P 865283-75-6P 865283-77-8P 865283-78-9P 865283-79-0P
865283-80-3P 878483-11-5P 880101-28-0P 880101-30-4P 880101-32-6P
880101-34-8P 880101-36-0P 880101-72-4P 880101-73-5P 880101-85-9P
880101-86-0P 880101-87-1P 880101-88-2P 880101-89-3P 880102-38-5P
880102-39-6P 880102-40-9P 880102-41-0P 880102-42-1P 880102-43-2P
880102-44-3P 880102-45-4P 880102-49-8P 880102-50-1P 880102-51-2P
880102-52-3P 880102-53-4P 880102-55-6P 880102-56-7P 880102-58-9P
880102-60-3P 880102-61-4P 880102-62-5P 880102-65-8P 880102-66-9P
880102-68-1P 880103-37-7P 880103-38-8P 880103-40-2P 880135-96-6P
880135-97-7P 880135-98-8P 880135-99-9P 880136-00-5P 880136-11-8P
880136-12-9P 880136-13-0P 880136-14-1P 880136-15-2P 880136-16-3P
880136-23-2P 880136-29-8P 880136-30-1P 880136-34-5P 880136-44-7P
880136-45-8P 880136-47-0P 880136-48-1P 880136-53-8P 880136-55-0P
880136-57-2P 880136-60-7P 880136-62-9P 880136-66-3P 880141-09-3P
880141-11-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 865283-76-7P 880101-90-6P
RL: RGT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 878483-10-4P 880101-27-9P 880101-29-1P 880101-31-5P 880101-33-7P
880101-35-9P 880101-37-1P 880103-39-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial synthesis of MUC1 glycopeptides via polymer

blotting)

IT 137010-42-5, BLase
RL: CAT (Catalyst use); USES (Uses)
(of Bacillus licheniformis, glycopeptide cleavage from solid phase with; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 52-90-4, L-Cysteine, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reacting the compds. of formula (I) with solid phase support containing; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

IT 7631-86-9, Silica, uses
RL: TEM (Technical or engineered material use); USES (Uses)
(solid phase support of; combinatorial synthesis of MUC1 glycopeptides via polymer blotting)

L7 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1240544 CAPLUS
DOCUMENT NUMBER: 144:2843
TITLE: Method and kit for detecting components in a sample
INVENTOR(S): Ramael, Marc
PATENT ASSIGNEE(S): Belg.
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111619	A1	20051124	WO 2004-EP4547	20040429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1740951	A1	20070110	EP 2004-730243	20040429 <--
EP 1740951	B1	20080305		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007534948	T	20071129	JP 2007-509881	20040429 <--
AT 388404	T	20080315	AT 2004-730243	20040429 <--
US 20080269064	A1	20081030	US 2006-587710	20061026 <--

PRIORITY APPLN. INFO.: WO 2004-EP4547 W 20040429 <--

AB The present invention relates to methods and kit for use in the detection of a component in a sample on a solid support, comprising the use of a conjugate and polymer comprising metal particles of diameter in the nanometer range (i.e. between 0.1 and 500 nm). It further relates to methods and kit for use in the detection of a component in a sample on a solid support, comprising the use of conjugate and optionally polymer bound to one or more supermagnetic particles. It further relates to methods and kit for use in enhancing in vivo imaging and microscopy. Microarrays were printed using specific oligonucleotides detecting HPV 16, HPV18, HPV 31, HPV 33, HPV 35, HPV 52 and HPV 58. The hybridization assay was set up using PCR amplified HPV DNA. During the PCR reaction, the

amplification product was labeled using a biotin labeled primer. Slides were visualized by treatment with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm and signal amplification with dextran polymer or poly-L-lysine polymer coated with numerous biotin mols., anti-biotin antibody or streptavidin labeled with gold nanoparticles, and metal enhancement. Hybridized microarrays showed areas with very sharp black or red colored spots in some areas depending on the used substrate. Other areas did not show any signal. Background signal was completely absent.

TI Method and kit for detecting components in a sample

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI WO 2004-EP4547 W 20040429 <--

AB The present invention relates to methods and kit for use in the detection of a component in a sample on a solid support, comprising the use of a conjugate and polymer comprising metal particles of diameter in the nanometer range (i.e. between 0.1 and 500 nm). It further relates to methods and kit for use in the detection of a component in a sample on a solid support, comprising the use of conjugate and optionally polymer bound to one or more supermagnetic particles. It further relates to methods and kit for use in enhancing in vivo imaging and microscopy. Microarrays were printed using specific oligonucleotides detecting HPV 16, HPV18, HPV 31, HPV 33, HPV 35, HPV 52 and HPV 58. The hybridization assay was set up using PCR amplified HPV DNA. During the PCR reaction, the amplification product was labeled using a biotin labeled primer. Slides were visualized by treatment with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm and signal amplification with dextran polymer or poly-L-lysine polymer coated with numerous biotin mols., anti-biotin antibody or streptavidin labeled with gold nanoparticles, and metal enhancement. Hybridized microarrays showed areas with very sharp black or red colored spots in some areas depending on the used substrate. Other areas did not show any signal. Background signal was completely absent.

ST kit conjugate polymer metal particle assay; DNA microarray HPV polymer enhanced metal amplification visualization

IT Ankyrins
Cadherins
Fibrillins
Presenilins
Thrombospondins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Presenilins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Metallothioneins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclin dependent kinase inhibitors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2B; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in

samples)
IT Connexins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(32; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Connexins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(43; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Apolipoproteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(A-I; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ABCA1 (ATP-binding cassette transporter subfamily A member 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ABCA4 (ATP-binding cassette transporter subfamily A member 4); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ABCB1 (ATP-binding cassette transporter sub-family B member 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Blood-group substances
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ABO; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ATM (ataxia telangiectasia mutated); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ATP6B1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ATRX; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Abl2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Apaf-1 (apoptotic protease activating factor-1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Growth factor receptors
Tyrosine kinase receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Axl; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Apolipoproteins
Interleukin 12
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(B; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BAG-1 (Bcl2-associated athanogene 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BAK1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BCL2-like 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BCL2A1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BCR; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BIK (Bcl-2-interacting killer); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BRCA1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(BRCA2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Bad; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Bax; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Bcl-2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Apolipoproteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(C-III; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(C/EBP-β (CCAAT box/enhancer element-binding protein β); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CBP (CREB-binding protein); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Chemokine receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CCR2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT CD antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD106; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT CD antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(CD18; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT CD antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD54; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT G proteins (guanine nucleotide-binding proteins)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CDC42; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CRK; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Chemokine receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CXCR4; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(D1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DCC (deleted in colorectal cancer); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DMBT1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Enzymes, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DNA helicase BLM; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DSCR1 (Down syndrome critical region 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Dopamine receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(D2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in

samples)
IT Dopamine receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(D4; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Selectins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E2A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E2F1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Apolipoproteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Egr-1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT EphB receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(EphB2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Gene, animal
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FHIT; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FMR-1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FOS (fosfomycin resistance); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(FRD; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(GADD45; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(GLUT-1 (glucose transporter 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(GRB-2 (growth factor receptor-bound protein 2); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Neuregulin receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HER3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HIF-1α (hypoxia-inducible factor 1α); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Histocompatibility antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA-A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Histocompatibility antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA-B; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Histocompatibility antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HLA-C; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HNF-4 (hepatocyte nuclear factor 4); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Heat-shock proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(HSP 27, 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Heat-shock proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(HSP 90α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Fibronectins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(I; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cell adhesion molecules
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ICAM-1 (intercellular adhesion mol. 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Insulin-like growth factor-binding proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IGFBP-3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IRS-1 (insulin receptor substrate 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ISGF-2 (interferon-stimulated gene factor 2); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IgE, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(IgG, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Jo-1, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cell adhesion molecules
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Leu-CAM (leukocytic cell adhesion mol.); kit and method using solid support, conjugate and polymer comprising metal particles for

detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MADH2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MLH1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MSH2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Mucins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MUC1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MeCP2 (Me CpG-binding protein 2); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(N-myc; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NFKB1 (nuclear factor of κ light chain gene enhancer in B-cells, 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NFKB1α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NFKB2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NM23; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Imaging
(NMR; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Nuclear receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NR3C1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Notch (receptor)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Notch3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PABP (poly(A)-binding protein), cytoplasmic 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PDZ domain-containing, 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PML; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PMP-22 (peripheral myelin protein, 22 kDa); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PPP3R1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PRKDC; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PTEN; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Pax3; kit and method using solid support, conjugate and polymer

comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Pax6; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RAD51; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Guanine nucleotide exchange factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RALGDS (RAL guanine nucleotide dissociation stimulator); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Retinoic acid receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RAR-α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Retinoic acid receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RAR-β; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RUNX1 (runt-related transcription factor 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Retinoid X receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RXRα; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT G proteins (guanine nucleotide-binding proteins)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Rac1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Rb; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RelA; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Rho protein (G protein)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(RhoA; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Ro/SSA, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Sodium channel
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SCN5A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Chemokines
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SDF-1 (stromal-derived factor-1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SHCA (SH2 domain-containing protein A); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SIRP-α (signal regulatory protein-α); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(SREBP-1 (sterol regulatory element-binding protein 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(STAT1 (signal transducer and activator of transcription 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(STAT3 (signal transducer and activator of transcription 3); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(STAT5A (signal transducer and activator of transcription 5A); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(STAT6 (signal transducer and activator of transcription 6); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Scl-70, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antigens
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Sm, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Smad-4; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Sp1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TCF-1 (T-cell factor 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TEL; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transforming growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TGF-β receptor, type I; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transforming growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TGF-β receptor, type II; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transforming growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TGF-β receptor, type V; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TSC2 (tuberous sclerosis complex 2); kit and method using solid

support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TSSC3 (tumor suppressing subtransferable candidate 3); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Neurotrophic factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(TrkA; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cell adhesion molecules
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(VCAM-1 (vascular cell adhesion mol. 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Myosins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(VII, A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(WT1 (Wilms' tumor suppressor 1); kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(XPA (xeroderma pigmentosa A)-complementing; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(XPC (xeroderma pigmentosa C)-complementing; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(YWHAZ; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(abl1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Samples
(anal. of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Toxins
RL: ANT (Analyte); ANST (Analytical study)

(anthrax lethal factor, oligonucleotides derived from genome for; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
Nucleic acids
Peptide nucleic acids
Peptides, biological studies
Proteins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(as probe; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 31
Human papillomavirus 33
Human papillomavirus 35
Human papillomavirus 52
Human papillomavirus 58
(assay probe binding to gene of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Gene, microbial
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(assay probe binding to human papillomavirus; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Human papillomavirus
(assay probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ataxins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ataxin-1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(autoantibodies, antinuclear antibody, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Animal tissue
(biol. staining of components in sections of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cell
(biol. staining of components in; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Albumins, biological studies
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biotinylated and labeled with gold particles; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biotinylated; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Neurotrophic factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(brain-derived; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ras proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(c-Ki-ras2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(c-Raf; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(c-jun; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(calcium pump SERCA2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Color
(chart, for reading assay results; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cholesterol ester-exchanging; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(circulating, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(coat, assay probe binding to human papillomavirus; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Probes (nucleic acid)
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DEV (Device component use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(coated slides printed with; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Polymers, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(conjugates with metal particles and biotin; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Albumins, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(conjugates, with metal particles and biotin; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Nucleic acids
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(conjugates, with solid support; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Microorganism
(contaminants of drinking water, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(copper transporter ATP7A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(copper-transporter ATP7B; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Nervous system, disease
(degeneration, detection, diagnosis, or monitoring of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Electric conductivity
Electric current
(detecting changes in, across solid support, for reading assay results; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Magnetic field
Surface plasmon resonance
(detecting changes in, on solid support, for reading assay results; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Listeria
Salmonella
(detection in food; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Autoimmune disease
Neoplasm
(detection, diagnosis, or monitoring of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Allergy
(diseases related to, detection, diagnosis, or monitoring of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(dopamine transporter, SLC6A3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Translation elongation factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(eEF-1α1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Eubacteria
(environmental testing of water for; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fyn; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Agglutinins and Lectins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(galectin-3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(gene BCL6; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(gene EWS; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(gene HFE; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Myosins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(heavy chain, 7; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Enzymes, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(helicase ERCC2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Enzymes, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(helicase ERCC5; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(huntingtin; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Antibodies and Immunoglobulins
Proteins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(immobilized; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(junB; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT DNA microarray technology
Diagnosis
Environmental analysis
Food analysis
Human
Imaging
Immunohistochemistry
Microscopy
Nucleic acid hybridization
PCR (polymerase chain reaction)
Solids
Staining, biological
Susceptibility (genetic)
Test kits
(kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT APC protein
Amyloid precursor proteins
Androgen receptors
Angiotensin AT1 receptors
Aromatic hydrocarbon receptors
Bone morphogenetic protein 2
Bone morphogenetic protein 4
CD14 (antigen)
CD36 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD44 (antigen)
CD45 (antigen)
CFTR (cystic fibrosis transmembrane conductance regulator)
Clusterin
Dystrophin
Endoglins
Epidermal growth factor receptors
Fas antigen
Fas ligand
Gelsolin
Glucagon receptors
Growth hormone receptors
Hepatocyte growth factor
Hepatocyte growth factor receptors
Insulin receptors

Insulin-like growth factor I receptors
Insulin-like growth factor II receptors
Interleukin 1 receptor antagonist
Interleukin 12
Interleukin 1α
Interleukin 1β
Interleukin 2
Interleukin 4
Interleukin 4 receptors
Interleukin 5
Interleukin 6
Interleukin 8
Leptin receptors
Leukemia inhibitory factor
Lymphotoxin
Macrophage colony-stimulating factor receptors
Macrophage inflammatory protein 1β
Mdm2 protein
Monocyte chemoattractant protein-1
Myelin basic protein
Neuregulin 1
Neurofibromin
Osteonectin
Osteopontin
Proliferating cell nuclear antigen
Prostate-specific antigen
RANTES (chemokine)
Rhodopsins
Secretin receptors
Tau factor
Thyrotropin receptors
Transferrin receptors
Transferrins
Transthyretin
Tumor necrosis factors
Vimentins
Vitamin D receptors
c-Kit (protein)
neu (receptor)
p53 (protein)
α-Fetoproteins
β1-Adrenoceptors
β3-Adrenoceptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Primers (nucleic acid)
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Nucleic acids
Proteins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(labeled, with biotin; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(labeled, with gold particles; kit and method using solid support,

conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(lamins, A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(lamins, C; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Reagents
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(metal enhancement; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Nanoparticles
Particles
(metal; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal, labeled with gold particles; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(myb; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transcription factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(myc; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(neurofibromin 2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclin dependent kinase inhibitors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p16INK4A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclin dependent kinase inhibitors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p21CIP1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ras proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p21Ha-ras; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ras proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p21N-ras; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclin dependent kinase inhibitors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p27KIP1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Cyclin dependent kinase inhibitors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(p57KIP2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Metals, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(particles, conjugates; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(patched; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ligands
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide, as probe; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pim-1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(polycystin 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Phosphoproteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(pp56lck; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Drinking waters
(probe binding to microorganism contaminants of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Hepatitis B virus

Hepatitis C virus
Human T-lymphotropic virus
Human immunodeficiency virus
Mycobacterium
Staphylococcus aureus
(probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Ribonucleoproteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(prosaposins; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Carcinoma
(pulmonary squamous cell, immunohistochem. staining of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Neurotrophic factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ret; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Transport proteins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(serotonin transporter SLC6A4; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Silanes
RL: DEV (Device component use); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(slides coated with; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Hedgehog protein
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(sonic; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Lung, neoplasm
(squamous cell carcinoma, immunohistochem. staining of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Paramagnetic materials
(superparamagnetic, particles; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Gene
RL: ANT (Analyte); BSU (Biological study, unclassified); FFD (Food or feed use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(testing food for components with modified; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Fibroblast growth factor receptors
Laminin receptors
Tumor necrosis factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Fibroblast growth factor receptors
Tumor necrosis factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type 2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Fibroblast growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type 3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 5-HT receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type 5-HT2A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Collagens, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type I, α1 or α2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Estrogen receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type I; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Collagens, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type II, α1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Collagens, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type III, α1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Vascular endothelial growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type VEGFR-1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Vascular endothelial growth factor receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(type VEGFR-2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components

in samples)
IT Infection
(viral, with human papillomavirus, detection of; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Potassium channel
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(voltage-gated, Kv11.1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Potassium channel
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(voltage-gated, Kv7.1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Calcium channel
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(voltage-gated, α1 subunit; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Fibrinogens
Interleukin 2 receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α chain; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Actins
Catenins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α-, 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Tropomyosins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Nicotinic receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α7; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Peroxisome proliferator-activated receptors
Platelet-derived growth factor receptors
Thyroid hormone receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Tubulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α1-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in

samples)
IT Integrins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α5; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Hemoglobins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β chain; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Catenins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β-, 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Amyloid
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β-, probe binding to; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Actins
Tubulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transforming growth factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β1-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Transforming growth factors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β2-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Estrogen receptors
Platelet-derived growth factor receptors
Platelet-derived growth factors
Thyroid hormone receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Crystallins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(βB1-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT Integrins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(β1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Microglobulins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β2-; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Integrins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(β3; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Fibrinogens
Interleukin 2 receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(γ chain; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Actins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(γ-, 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Interferon receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(γ-interferon; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT Interferons
Peroxisome proliferator-activated receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(γ; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9054-89-1, Superoxide dismutase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(1 and 2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9013-66-5, Glutathione peroxidase 9016-12-0, Hypoxanthine phosphoribosyl transferase 9048-63-9, Epoxide hydrolase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9014-08-8, Enolase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(1α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9028-86-8, Aldehyde dehydrogenase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 125978-95-2, Nitric oxide synthase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9001-51-8, Hexokinase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(4; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9001-66-5 9024-52-6
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 74812-49-0, Ubiquitin protein ligase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(E3A; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9001-03-0
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(II; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9027-33-2, Arylamine Acetyltransferase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(NAT2; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 50812-37-8, Glutathione S-transferase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P1, M1 and theta 1; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9023-93-2, Acetyl-Coenzyme A carboxylase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 7440-22-4, Silver, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(enhancement reagent; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 9001-84-7, Phospholipase A2
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(group IIA; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in

samples)

IT 9000-81-1, Acetylcholinesterase 9001-12-1, Matrix metalloproteinase 1 9001-24-5, Blood-coagulation factor V 9001-25-6, Blood-coagulation factor VII 9001-28-9, Blood-coagulation factor IX 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-48-3, Glutathione reductase 9001-50-7, Glyceraldehyde-3-phosphate dehydrogenase 9001-78-9 9002-03-3, Dihydrofolate reductase 9002-10-2, Tyrosinase 9004-02-8, Lipoprotein lipase 9012-25-3, Catechol-O-methyltransferase 9015-82-1, Angiotensin I converting enzyme 9016-11-9, Galactose-1-phosphate uridylyltransferase 9026-89-5, Dihydropyrimidine dehydrogenase 9026-93-1, Adenosine deaminase 9028-35-7, 3-Hydroxy-3-methylglutaryl-Coenzyme A reductase 9029-73-6, Phenylalanine hydroxylase 9031-14-5, Lecithin-cholesterol acyltransferase 9035-58-9, Blood-coagulation factor III 9054-63-1 11002-13-4, Angiotensinogen 58319-92-9, ADP-ribosyltransferase 60616-82-2, Cathepsin L 62229-50-9, Epidermal growth factor 63551-76-8, Phospholipase C γ1 67763-96-6, Insulin-like growth factor 1 67763-97-7, Insulin-like growth factor-2 71822-25-8, 5,10-Methylenetetrahydrofolate reductase 79955-99-0, Matrix metalloproteinase 3 82707-54-8, Membrane metalloendopeptidase 83869-56-1, Colony-stimulating factor 2 94716-09-3, Cathepsin K 106096-93-9, FGF2 109319-16-6 113189-02-9, Blood-coagulation factor VIII 117698-12-1, Paraoxonase 1 120178-12-3, Telomerase reverse transcriptase 122191-40-6, Caspase 1 124861-55-8 127464-60-2, VEGF 137632-08-7, Mitogen-activated protein kinase 1 138069-86-0, APEX nuclease 139639-23-9, Tissue plasminogen activator 140208-24-8, TIMP1 141349-86-2, Cyclin-dependent kinase 2 141436-78-4, Protein kinase C α 143375-65-9 144114-16-9, Protein tyrosine kinase 2 144697-17-6, c-Src tyrosine kinase 145809-21-8, TIMP3 146480-36-6, Matrix metalloproteinase 9 147014-96-8, Cyclin-dependent kinase 5 147230-71-5, FLT3 kinase 148640-14-6, AKT1 kinase 151662-26-9 157482-36-5, Janus kinase 3 161384-17-4, Matrix metalloproteinase 14 165245-96-5, Mitogen-activated protein kinase 14 169592-56-7, Caspase 3 175449-82-8, Matrix metalloproteinase 13 176023-60-2, AKT2 kinase 179241-78-2, Caspase 8 180189-96-2, Caspase 9 182372-14-1, Caspase 2 182372-15-2, Caspase 6 182762-08-9, Caspase 4 189088-85-5, Caspase 10 189258-14-8, Caspase 7 189460-40-0, Connective tissue growth factor 202420-40-4, Serine-threonine protein kinase 11 216864-07-2, α-Synuclein 306298-47-5, Dual specificity phosphatase 1 329764-85-4, Cytochrome P 450 1A1 329967-85-3 330207-13-1, Cytochrome P 450 2C8 330589-90-7, Cytochrome P 450 2C19 330596-22-0, Cytochrome P 450 1B1 330824-80-1, Cytochrome P450 21A2 331827-06-6, Cytochrome P 450 2A6 334679-13-9, Cytochrome P 450 2E 336874-97-6, Cytochrome P 450 3A5 440365-05-9, Cytochrome P 450 17 440367-91-9, Cytochrome P 450 19 443900-95-6, Glycogen synthase kinase 3β 472998-88-2, Protein kinase C ζ 503473-02-7, Nitric oxide synthase 3 553648-93-4, Glycogen synthase kinase 3α 657407-83-5, Calpain 3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

IT 7429-90-5D, Aluminum, conjugates 7439-89-6D, Iron, conjugates 7439-92-1D, Lead, conjugates 7439-93-2D, Lithium, conjugates 7439-95-4D, Magnesium, conjugates 7439-96-5D, Manganese, conjugates 7439-98-7D, Molybdenum, conjugates 7440-02-0D, Nickel, conjugates 7440-03-1D, Niobium, conjugates 7440-06-4D, Platinum, conjugates 7440-15-5D, Rhenium, conjugates 7440-16-6D, Rhodium, conjugates 7440-21-3D, Silicon, conjugates 7440-26-8D, Technetium, conjugates 7440-31-5D, Tin, conjugates 7440-32-6D, Titanium, conjugates 7440-33-7D, Wolfram, conjugates 7440-35-9D, Americium, conjugates 7440-36-0D, Antimony, conjugates 7440-43-9D, Cadmium, conjugates 7440-46-2D, Cesium, conjugates 7440-47-3D, Chromium, conjugates

7440-50-8D, Copper, conjugates 7440-53-1D, Europium, conjugates
7440-54-2D, Gadolinium, conjugates 7440-56-4D, Germanium, conjugates
7440-57-5D, Gold, conjugates 7440-61-1D, Uranium, conjugates
7782-49-2D, Selenium, conjugates 9004-54-0D, Dextran, conjugates with
metal particles and biotin 13494-80-9D, Tellurium, conjugates
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising
metal particles for detecting components in samples)

IT 58-85-5D, Biotin, conjugates with probes or with metal
particle-bound polymers or with sample 9013-20-1D, Streptavidin,
complexes with metal particles 25104-18-1D, Poly-L-lysine,
conjugates with biotin labeled with gold particles 28718-90-3D,
4',6-Diamidino-2-phenylindole dihydrochloride, conjugates with
streptavidin 38000-06-5D, Poly-L-lysine, conjugates with biotin labeled
with gold particles
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising
metal particles for detecting components in samples)

IT 7440-22-4D, Silver, conjugates
RL: ARG (Analytical reagent use); RCT (Reactant); ANST (Analytical study);
RACT (Reactant or reagent); USES (Uses)
(kit and method using solid support, conjugate and polymer comprising
metal particles for detecting components in samples)

IT 869616-78-4
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(nucleotide sequence, oligo op drager; kit and method using solid
support, conjugate and polymer comprising metal particles for
detecting components in samples)

IT 869616-77-3
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(nucleotide sequence, target; kit and method using solid support,
conjugate and polymer comprising metal particles for
detecting components in samples)

IT 869616-79-5
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(nucleotide sequence, visualization oligo; kit and method using solid
support, conjugate and polymer comprising metal particles for
detecting components in samples)

IT 9003-99-0, Myeloperoxidase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(probe binding to; kit and method using solid support, conjugate and
polymer comprising metal particles for detecting components
in samples)

IT 9035-37-4, Cytochrome b
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(redox potential -245; kit and method using solid support, conjugate
and polymer comprising metal particles for detecting
components in samples)

IT 9004-70-0, Nitrocellulose 108317-04-0, Nytran
RL: DEV (Device component use); RCT (Reactant); RACT (Reactant or
reagent); USES (Uses)
(slides coated with; kit and method using solid support, conjugate and
polymer comprising metal particles for detecting components
in samples)

IT 1317-61-9, Iron oxide, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(superparamagnetic particles, complexes with streptavidin; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)
IT 142805-56-9
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(α; kit and method using solid support, conjugate and polymer comprising metal particles for detecting components in samples)

L7 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1075818 CAPLUS
DOCUMENT NUMBER: 143:361535
TITLE: Combinatorial libraries of A chain insertion variants of Shiga-like toxins for development of toxins with new activities or properties
INVENTOR(S): Gariepy, Jean; Wei, Xin
PATENT ASSIGNEE(S): Can.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092917	A1	20051006	WO 2004-CA443	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, TD, TG				
AU 2004317555	A1	20051006	AU 2004-317555	20040326 <--
CA 2559536	A1	20051006	CA 2004-2559536	20040326 <--
EP 1727827	A1	20061206	EP 2004-785852	20040326 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007531716	T	20071108	JP 2007-504218	20040326 <--
US 20070298434	A1	20071227	US 2007-598965	20070226 <--
PRIORITY APPLN. INFO.:			WO 2004-CA443 A	20040326 <--

AB Libraries of Shiga-like toxin A-chains containing small insertions, typically less than 10 amino acids, at defined sites in the protein, are described. These variants may have unexpected activities or novel binding specificities may be obtained. A small library of 3000 peptides containing a tripeptide insertion in the C-terminal loop of the A chain was constructed using an Escherichia coli expression host. The A chains were manufactured in an Escherichia coli expression host as complexes with the B-chain and captured immobilized metal ion affinity chromatog. These were then screened for a MUC1 mucin epitope and two variants reacting with a monoclonal antibody to MUC1 were identified. A more complex library containing heptapeptide inserts at the same site was screened for variants that were cytotoxic to human cancer cell lines. A first screening of 5,000 colonies identified seven variants effective against

the melanoma line 518A2. Upon rescreening, they were found to be effective against other cancer cell lines.

TI Combinatorial libraries of A chain insertion variants of Shiga-like toxins for development of toxins with new activities or properties

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI WO 2004-CA443 A 20040326 <--

AB Libraries of Shiga-like toxin A-chains containing small insertions, typically less than 10 amino acids, at defined sites in the protein, are described. These variants may have unexpected activities or novel binding specificities may be obtained. A small library of 3000 peptides containing a tripeptide insertion in the C-terminal loop of the A chain was constructed using an Escherichia coli expression host. The A chains were manufactured in an Escherichia coli expression host as complexes with the B-chain and captured immobilized metal ion affinity chromatog. These were then screened for a MUC1 mucin epitope and two variants reacting with a monoclonal antibody to MUC1 were identified. A more complex library containing heptapeptide inserts at the same site was screened for variants that were cytotoxic to human cancer cell lines. A first screening of 5,000 colonies identified seven variants effective against the melanoma line 518A2. Upon rescreening, they were found to be effective against other cancer cell lines.

L7 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1020555 CAPLUS

DOCUMENT NUMBER: 143:320266

TITLE: Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ

INVENTOR(S): Ueda, Minoru; Yamada, Yoichi

PATENT ASSIGNEE(S): Hitachi Medical Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005253442	A	20050922	JP 2004-111582	20040309 <--

PRIORITY APPLN. INFO.: JP 2004-111582 20040309 <--

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by

2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

TI Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ

PRAI JP 2004-111582 20040309 <--

IT Mucins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1, episialin variant A; genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ)

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (proton-coupled divalent metal ion transporters, gene SLC11A2; genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ)

L7 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:984043 CAPLUS

DOCUMENT NUMBER: 143:284109

TITLE: Diagnosis and prevention of hyperinsulinemia and type II diabetes using patterns of gene expression in muscle cells

INVENTOR(S): Kopchick, John J.; Coschigano, Karen T.; Boyce, Keith S.; Kriete, Andres

PATENT ASSIGNEE(S): Ohio University, USA; Icoria, Inc.

SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082398	A2	20050909	WO 2005-US5596	20050224 <--
WO 2005082398	A3	20060126		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005216922	A1	20050909	AU 2005-216922	20050224 <--
CA 2557181	A1	20050909	CA 2005-2557181	20050224 <--
EP 1732582	A2	20061220	EP 2005-713932	20050224 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-547512P P	20040226 <--
			US 2004-579342P P	20040615 <--
			WO 2005-US5596 W	20050224

AB Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic muscle by gene chip anal. have been identified, as have corresponding human genes and proteins. The human mols., or antagonists thereof, may be used for protection against hyperinsulinemia or type 2

diabetes, or their sequelae.
TI Diagnosis and prevention of hyperinsulinemia and type II diabetes using patterns of gene expression in muscle cells
PRAI US 2004-547512P P 20040226 <--
US 2004-579342P P 20040615 <--
WO 2005-US5596 W 20050224
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(MUC1, gene for; diagnosis and prevention of hyperinsulinemia and type II diabetes using patterns of gene expression in muscle cells)
IT Transport proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(proton-coupled divalent metal ion transporters, gene for; diagnosis and prevention of hyperinsulinemia and type II diabetes using patterns of gene expression in muscle cells)

L7 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:902703 CAPLUS
DOCUMENT NUMBER: 143:272498
TITLE: Gene expression profiles in the diagnosis and treatment of Alzheimer's disease
INVENTOR(S): Landfield, Philip W.; Porter, Nada M.; Chen, Kuey Chu; Geddes, James; Blalock, Eric
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076939	A2	20050825	WO 2005-US3668	20050209 <--
WO 2005076939	A3	20060706		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070082350	A1	20070412	US 2006-501226	20060809
PRIORITY APPLN. INFO.:			US 2004-542281P P	20040209 <--
			WO 2005-US3668 A	20050209

AB Genes showing altered patterns of expression in the brain that are associated with the neurol. changes found in Alzheimer's disease and that can be used in the early diagnosis of the disease, including the incipient form of the disease, are identified. The methods and kits of the invention utilize a set of genes and their encoded proteins that are shown to be correlated with incipient Alzheimer's disease.
TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease
PRAI US 2004-542281P P 20040209 <--
WO 2005-US3668 A 20050209
IT Gene, animal

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ADAM17, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

IT Gene, animal
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ADCY9, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

IT Gene, animal
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DARS, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

L7 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696640 CAPLUS
DOCUMENT NUMBER: 143:199740
TITLE: Onconase complex conjugated with folate for diagnosis and treatment of cancer, infection, cardiovascular disorder and autoimmune disease
INVENTOR(S): Hansen, Hans J.; McBride, William J.; Goldenberg, David M.; Rossi, Edmund A.; Chang, Chien-Hsing Ken
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005069994	A2	20050804	WO 2005-US2193	20050124 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005207026	A1	20050804	AU 2005-207026	20050124 <--
CA 2553221	A1	20050804	CA 2005-2553221	20050124 <--
US 20050261170	A1	20051124	US 2005-40114	20050124 <--
EP 1732608	A2	20061220	EP 2005-722512	20050124 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007524412	T	20070830	JP 2006-551370	20050124 <--
PRIORITY APPLN. INFO.:			US 2004-538396P P	20040122 <--
			WO 2005-US2193 W	20050124

AB Because the folate receptor (also called the folate binding protein, FBP) is overexpressed on certain malignant cell types, targeting of the folate receptor has been proposed as a potential mechanism for delivery of drugs and/or radiopharmaceuticals to treat cancer. Onconase and/or variants with ribonucleolytic activity, such as rapLR1, present useful therapeutic

mols. for preparing folate conjugates and complexes. The conjugates and complexes can be targeted to and internalized by targeted tissues. The conjugates and complexes may be formulated with a pharmaceutically acceptable excipient to form a primary therapeutic agent. The conjugates and complexes may be useful as primary therapeutic agents, which may be administered with addnl. therapeutic or diagnostic agents. Also disclosed are kits that include the conjugates and complexes.

TI Onconase complex conjugated with folate for diagnosis and treatment of cancer, infection, cardiovascular disorder and autoimmune disease

PRAI US 2004-538396P P 20040122 <--
WO 2005-US2193 W 20050124

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1, tumor associated with; onconase complex conjugated with folate for diagnosis and treatment of cancer, infection, cardiovascular disorder and autoimmune disease)

IT Abrins
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 21
Interleukin 3
Interleukin 6
Metals, biological studies
Ricins
Taxanes
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combined with onconase complex for diagnosis and therapy; onconase complex conjugated with folate for diagnosis and treatment of cancer, infection, cardiovascular disorder and autoimmune disease)

```
=> s 11-29 ibib abs ti hit
      1059707 11
       326488 29
           16 IBIB
       247393 ABS
            4 ABSES
       247397 ABS
                (ABS OR ABSES)
       379053 TI
         1357 TIS
       380077 TI
                (TI OR TIS)
         9473 HIT
         4755 HITS
        13548 HIT
                (HIT OR HITS)
L8          0 11-29 IBIB ABS TI HIT
                (11(W)29(W)IBIB(W)ABS(W)TI(W)HIT)

=> s 11-29 ibib ti hit
      1059707 11
       326488 29
           16 IBIB
       379053 TI
         1357 TIS
       380077 TI
                (TI OR TIS)
```

```
         9473 HIT
         4755 HITS
        13548 HIT
                (HIT OR HITS)
L9            0 11-29 IBIB TI HIT
                (11(W)29(W)IBIB(W)TI(W)HIT)

=> d his

     (FILE 'HOME' ENTERED AT 15:49:54 ON 17 NOV 2008)

     FILE 'CAPLUS' ENTERED AT 15:51:55 ON 17 NOV 2008
L1         2906 S MUC1
L2            0 S L1(S)METAL(A)CHELATOR
L3            0 S L1(S)CHELATOR
L4            0 S MUC1 AND METAL CHELATOR
L5            7 S MUC1 AND CHELATOR
L6          484 S MUC1 AND (PRY<2005)
L7           29 S L6 AND METAL
L8            0 S 11-29 IBIB ABS TI HIT
L9            0 S 11-29 IBIB TI HIT

=> s l7
       1880500 METAL
        936792 METALS
       2276600 METAL
                (METAL OR METALS)
L10          29 L6 AND METAL

=> d 11-29 ibib abs ti hit

L10  ANSWER 11 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:638618  CAPLUS
DOCUMENT NUMBER:          143:131809
TITLE:                    Production of human monoclonal antibodies
INVENTOR(S):              Tamarkin, Lawrence; Paciotti, Giulio F.
PATENT ASSIGNEE(S):       Cytimmune Sciences, Inc., USA
SOURCE:                   PCT Int. Appl., 61 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2005065121        A2    20050721    WO 2004-US40785        20041202 <--
     WO 2005065121        A3    20051229
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2004311630        A1    20050721    AU 2004-311630         20041202 <--
     CA 2548179           A1    20050721    CA 2004-2548179        20041202 <--
     US 20050175583       A1    20050811    US 2004-4623           20041202 <--
```

```
     EP 1694301          A2    20060830    EP 2004-821049         20041202 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1925843          A     20070307    CN 2004-80041234       20041202 <--
     JP 2008504216       T     20080214    JP 2006-542857         20041202 <--
PRIORITY APPLN. INFO.:                     US 2003-526360P     P  20031202 <--
                                           WO 2004-US40785     W  20041202 <--
AB   The authors disclose compns. and methods for making human monoclonal
     antibodies.  The methods comprise tethered colloidal gold microparticle
     scaffolds that replicate the immune system components, particularly an
     antigen-presenting cell (APC) with costimulatory (B7) and adhesive (ICAM)
     components of the immune synapse.  Addnl., the present invention may
     further comprise synthetic T-cells.
TI   Production of human monoclonal antibodies
PRAI US 2003-526360P     P     20031202  <--
     WO 2004-US40785     W     20041202  <--
IT   Mucins
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (MUC1, colloidal gold conjugates; of artificial
        antigen-presenting cells stimulating human antibody response)
IT   Freeze drying
        (of colloidal metal microparticle artificial
        antigen-presenting cells)

L10  ANSWER 12 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:182915  CAPLUS
DOCUMENT NUMBER:          142:276366
TITLE:                    Method for detection of viruses, food or water
                          contamination and diagnosis of diseases using gold
                          particle-labeled antibodies and arrays
INVENTOR(S):              Ramael, Marc; Sanders, Jean-paul
PATENT ASSIGNEE(S):       Belg.
SOURCE:                   PCT Int. Appl., 77 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2005019820        A1    20050303    WO 2003-EP9393         20030825
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003260457        A1    20050310    AU 2003-260457         20030825 <--
     EP 1658497           A1    20060524    EP 2003-818265         20030825 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
     US 20060286546       A1    20061221    US 2006-569713         20060224 <--
PRIORITY APPLN. INFO.:                     WO 2003-EP9393      A  20030825 <--
AB   The present invention relates to methods for detection of viruses, food or
     water contamination and diagnosis of diseases using gold particle-labeled
     antibodies and arrays.  The invention further relates to a kit and method
```

for staining components in cell and tissue sections, based upon the aforementioned kit and method. Methods for detection of HPV and diagnosis of cancer and neurodegenerative diseases are provided.

TI Method for detection of viruses, food or water contamination and diagnosis of diseases using gold particle-labeled antibodies and arrays

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI WO 2003-EP9393 A 20030825 <--

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1, gene for; method for detection of viruses, food or water contamination and diagnosis of diseases using gold particle-labeled antibodies and arrays)

IT Metals, analysis
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(method for detection of viruses, food or water contamination and diagnosis of diseases using gold particle-labeled antibodies and arrays)

L10 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:121072 CAPLUS
DOCUMENT NUMBER: 142:217385
TITLE: Humanized and chimeric anti-CD19 antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases
INVENTOR(S): Hansen, Hans J.; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012493	A2	20050210	WO 2004-US24636	20040802 <--
WO 2005012493	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2534639	A1	20050210	CA 2004-2534639	20040802 <--
US 20050070963	A1	20050331	US 2004-903858	20040802 <--
US 7109304	B2	20060919		
EP 1648512	A2	20060426	EP 2004-779636	20040802 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007528209	T	20071011	JP 2006-522093	20040802 <--
US 20060257398	A1	20061116	US 2006-445410	20060601 <--
PRIORITY APPLN. INFO.:			US 2003-491282P	P 20030731 <--
			US 2004-903858	A3 20040802 <--
			WO 2004-US24636	W 20040802 <--

AB The present invention provides humanized, chimeric and human anti-CD19

antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.

TI Humanized and chimeric anti-CD19 antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases

PRAI US 2003-491282P P 20030731 <--
US 2004-903858 A3 20040802 <--
WO 2004-US24636 W 20040802 <--

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; humanized and chimeric anti-CD19 antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Metals, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-radioactive; humanized and chimeric anti-CD19 antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

L10 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:98817 CAPLUS
DOCUMENT NUMBER: 142:183318
TITLE: D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis
INVENTOR(S): McBride, William J.; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 62 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050025709	A1	20050203	US 2004-866180	20040614 <--
US 7172751	B2	20070206		
AU 2004268932	A1	20050310	AU 2004-268932	20040614 <--
CA 2529027	A1	20050310	CA 2004-2529027	20040614 <--
WO 2005021494	A2	20050310	WO 2004-US18646	20040614 <--
WO 2005021494	A9	20050714		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1633773	A2	20060315	EP 2004-776484	20040614 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2008504214	T	20080214	JP 2006-533737	20040614 <--
IN 2006CN00125	A	20070629	IN 2006-CN125	20060110 <--
IN 2006CN00128	A	20070629	IN 2006-CN128	20060110 <--
US 20070142296	A1	20070621	US 2006-640557	20061218 <--

PRIORITY APPLN. INFO.: US 2003-478403P P 20030613 <--
US 2004-866180 A1 20040614 <--
WO 2004-US18646 W 20040614 <--

OTHER SOURCE(S): MARPAT 142:183318

AB The present invention provides compds. of the formula X-R1-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1 (X)-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. Multi-specific antibodies against a targetable construct are used that are capable of carrying one or more diagnostic or therapeutic agents. By using this approach the characteristics of the chelator, metal chelate complex, therapeutic agent or diagnostic agent can be varied to accommodate differing applications, without raising new multi-specific antibodies. The present invention also provides methods of using these compds. in radioimmunotherapy and radiol. diagnosis and kits containing the compds.

TI D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI US 2003-478403P P 20030613 <--
US 2004-866180 A1 20040614 <--
WO 2004-US18646 W 20040614 <--

AB The present invention provides compds. of the formula X-R1-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1 (X)-D-[Dpr, Orn or Lys](A)-R2 (Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. Multi-specific antibodies against a targetable construct are used that are capable of carrying one or more diagnostic or therapeutic agents. By using this approach the characteristics of the chelator, metal chelate complex, therapeutic agent or diagnostic agent can be varied to accommodate differing applications, without raising new multi-specific antibodies. The present invention also provides methods of using these compds. in radioimmunotherapy and radiol. diagnosis and kits containing the compds.

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; labeled D-amino acid peptide conjugates in radioimmunotherapy and radiol. diagnosis)

L10 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:934484 CAPLUS
DOCUMENT NUMBER: 141:409779
TITLE: Polyvalent protein complexes including trivalent bispecific chimeric antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiological disorder and autoimmune disease
INVENTOR(S): Rossi, Edmund A.; Chang, Chien-Hsing; McBride, William

J.
PATENT ASSIGNEE(S): IBC Pharmaceuticals, USA; Immunomedics, Inc
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094613	A2	20041104	WO 2004-US12662	20040422 <--
WO 2004094613	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232928	A1	20041104	AU 2004-232928	20040422 <--
CA 2522819	A1	20041104	CA 2004-2522819	20040422 <--
US 20050003403	A1	20050106	US 2004-829388	20040422 <--
EP 1618181	A2	20060125	EP 2004-750590	20040422 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006526408	T	20061124	JP 2006-513283	20040422 <--
US 20080171855	A1	20080717	US 2007-830413	20070730 <--

PRIORITY APPLN. INFO.:
US 2003-464532P P 20030422 <--
US 2003-525391P P 20031124 <--
US 2004-829388 B3 20040422 <--
WO 2004-US12662 W 20040422 <--

AB The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 'v-regions', which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 'v-regions' can be used on each polypeptide, chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

TI Polyvalent protein complexes including trivalent bispecific chimeric antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiological disorder and autoimmune disease

PRAI US 2003-464532P P 20030422 <--
US 2003-525391P P 20031124 <--
US 2004-829388 B3 20040422 <--
WO 2004-US12662 W 20040422 <--

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; polyvalent protein complexes including trivalent bispecific chimeric antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Androgens
CA 125 (carbohydrate antigen)

CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD30 (antigen)
CD45 (antigen)
CD80 (antigen)
Carcinoembryonic antigen
Cytokines
Enzymes, biological studies
Epidermal growth factor receptors
Estrogens
FcεRII receptors
Growth factors, animal
Haptens
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 2
Interleukin 3
Interleukin 6
Invariant chain (class II antigen)
Lymphokines
Melanoma-associated antigens
Metals, biological studies
Nucleic acids
Progestogens
Prostate-specific antigen
Radionuclides, biological studies
Steroids, biological studies
Tenascins
Toxins
Tumor antigens
Tumor antigens
neu (receptor)
α-Fetoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyvalent protein complexes including trivalent bispecific chimeric antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

L10 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:934160 CAPLUS
DOCUMENT NUMBER: 141:388650
TITLE: Anti-CD74 immunoconjugates and their therapeutic and diagnostic uses
INVENTOR(S): Griffiths, Gary L.; Hansen, Hans J.; Goldenberg, David M.; Lundberg, Bo B.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 377,122.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040219203	A1	20041104	US 2003-706852	20031112 <--
US 6306393	B1	20011023	US 1999-307816	19990510 <--
US 7074403	B1	20060711	US 2000-590284	20000609 <--

```
     US 20020071807         A1    20020613    US 2001-965796          20011001 <--
     US 20030124058         A1    20030703    US 2002-314330          20021209 <--
     US 20030133930         A1    20030717    US 2003-350096          20030124 <--
     US 20040115193         A1    20040617    US 2003-377122          20030303 <--
     US 7312318             B2    20071225
     AU 2004247270          A1    20041223    AU 2004-247270          20040617 <--
     CA 2529496             A1    20041223    CA 2004-2529496         20040617 <--
     WO 2004110390          A2    20041223    WO 2004-US19238         20040617 <--
     WO 2004110390          A3    20050428
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1644729             A2    20060412    EP 2004-776666          20040617 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     JP 2007523857          T     20070823    JP 2006-517321          20040617 <--
     US 20050191300         A1    20050901    US 2005-104594          20050413 <--
     US 20060051349         A1    20060309    US 2005-222838          20050912 <--
     IN 2006CN00178         A     20070629    IN 2006-CN178           20060113 <--
     US 20070020265         A1    20070125    US 2006-534124          20060921 <--
     US 20080138333         A1    20080612    US 2007-754902          20070529 <--
     US 20080166342         A1    20080710    US 2007-867775          20071005 <--
PRIORITY APPLN. INFO.:                         US 1999-307816       A1 19990510 <--
                                               US 2000-590284       A1 20000609 <--
                                               US 2001-965796       A1 20011001 <--
                                               US 2002-360259P      P  20020301 <--
                                               US 2002-314330       A2 20021209 <--
                                               US 2003-350096       A2 20030124 <--
                                               US 2003-377122       A2 20030303 <--
                                               US 2003-478830P      P  20030617 <--
                                               US 1997-41506P       P  19970324 <--
                                               US 1998-38995        A2 19980312 <--
                                               US 1999-138284P      P  19990609 <--
                                               US 2003-706852       A  20031112 <--
                                               WO 2004-US19238      W  20040617 <--
                                               US 2005-104594       A3 20050413
```

AB Disclosed are compsns. that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compsns. may be part of a kit for administering the anti-CD74 immunoconjugates compsns. in therapeutic and/or diagnostic methods. Anti-CD74 binding mols. are conjugated to the one or more lipids by one or more of a sulfide linkage, a hydrazone linkage, a hydrazine linkage, an ester linkage, an amido linkage, an amino linkage, an imino linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, a carbon-carbon linkage. Anti-CD74 immunoconjugates comprise a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, a cytokine, a hormone, an antibody., an oligonucleotide, or a photodynamic agent.

```
TI   Anti-CD74 immunoconjugates and their therapeutic and diagnostic uses
PRAI US 1999-307816         A1    19990510  <--
     US 2000-590284         A1    20000609  <--
     US 2001-965796         A1    20011001  <--
     US 2002-360259P        P     20020301  <--
```

```
     US 2002-314330       A2    20021209  <--
     US 2003-350096       A2    20030124  <--
     US 2003-377122       A2    20030303  <--
     US 2003-478830P      P     20030617  <--
     US 1997-41506P       P     19970324  <--
     US 1998-38995        A2    19980312  <--
     US 1999-138284P      P     19990609  <--
     US 2003-706852       A     20031112  <--
     WO 2004-US19238      W     20040617  <--
     US 2005-104594       A3    20050413
IT   Mucins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (MUC1, immunoconjugates binding to; anti-CD74
        immunoconjugates and their therapeutic and diagnostic uses)
IT   Actinides
     Rare earth metals, biological studies
     Transition metals, biological studies
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (ions; anti-CD74 immunoconjugates and their therapeutic and diagnostic
        uses)

L10  ANSWER 17 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:838610  CAPLUS
DOCUMENT NUMBER:          141:312238
TITLE:                    DNA microarray analysis of gene expression in the
                          diagnosis of estrogen receptor positive- and
                          negative-breast cancer
INVENTOR(S):              Erlander, Mark G.; Ma, Xiao-Jun; Wang, Wei; Wittliff,
                          James L.
PATENT ASSIGNEE(S):       Arcturus Bioscience, Inc., USA
SOURCE:                   PCT Int. Appl., 226 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2004079014        A2    20040916    WO 2002-XA2004006736   20040304 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     WO 2004079014        A2    20040916    WO 2004-US6736         20040304 <--
     WO 2004079014        A3    20050331
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2003-451942P     P  20030304 <--
```

WO 2004-US6736 A 20040304 <--

AB The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are pos. and neg. for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination
of prognosis of a patient, including breast cancer survival.

TI DNA microarray analysis of gene expression in the diagnosis of estrogen receptor positive- and negative-breast cancer

PRAI US 2003-451942P P 20030304 <--
WO 2004-US6736 A 20040304 <--

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1, gene for, in diagnosis of breast cancer; DNA microarray anal. of gene expression in diagnosis of estrogen receptor pos.- and neg.-breast cancer)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SLC11A3 (proton-coupled divalent metal iontransporter), gene for, in diagnosis of breast cancer; DNA microarray anal. of gene expression in diagnosis of estrogen receptor pos.- and neg.-breast cancer)

L10 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:780933 CAPLUS
DOCUMENT NUMBER: 141:289016
TITLE: Aptamers and cyclen compounds and complexes for the detection, monitoring and treatment of cancer
INVENTOR(S): Bruce, James Ironside; Missailidis, Sotiris; Borbas, Katalin Eszter; Ferreira, Catia Sofia Matos
PATENT ASSIGNEE(S): The Open University, UK
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081574	A2	20040923	WO 2004-GB1028	20040310 <--
WO 2004081574	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2518783	A1	20040923	CA 2004-2518783	20040310 <--
EP 1601970	A2	20051207	EP 2004-719000	20040310 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1806585	A1	20070711	EP 2007-100346	20040310 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

```
     US 20070160526       A1    20070712    US 2006-548718          20060706 <--
PRIORITY APPLN. INFO.:                        GB 2003-5422          A  20030310 <--
                                              EP 2004-719000        A3 20040310 <--
                                              WO 2004-GB1028        W  20040310 <--
OTHER SOURCE(S):          CASREACT 141:289016; MARPAT 141:289016
AB   The invention discloses MUC1 aptamer ligands to MUC1,
     e.g. CGAATGGGCCCGTCCTCGCTGTAAG, as well as compds. comprising these
     aptamers.  Also disclosed are substituted and metal-complexed
     cyclen compds.  Further disclosed are methods for treatment, diagnosis,
     detection and imaging using these compds., their use in such methods, and
     their use in the preparation of medicaments and products for such methods.
TI   Aptamers and cyclen compounds and complexes for the detection, monitoring
     and treatment of cancer
PRAI GB 2003-5422          A     20030310  <--
     EP 2004-719000        A3    20040310  <--
     WO 2004-GB1028        W     20040310  <--
AB   The invention discloses MUC1 aptamer ligands to MUC1,
     e.g. CGAATGGGCCCGTCCTCGCTGTAAG, as well as compds. comprising these
     aptamers.  Also disclosed are substituted and metal-complexed
     cyclen compds.  Further disclosed are methods for treatment, diagnosis,
     detection and imaging using these compds., their use in such methods, and
     their use in the preparation of medicaments and products for such methods.
ST   MUC1 aptamer cyclen prepn metal complex therapeutic
     diagnostic cancer
IT   Mucins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (MUC1; aptamers and cyclen compds. and complexes for
        detection, monitoring and treatment of cancer)
IT   294-90-6D, Cyclen, derivs., metal complexes   7440-15-5D,
     Rhenium, complexes with cyclen derivs.   7440-15-5D, Rhenium, cyclen
     derivative complexes   7440-26-8D, Technetium, complexes with cyclen derivs.
     7440-26-8D, Technetium, cyclen derivative complexes   7440-65-5D, Yttrium,
     complexes with cyclen derivs.   7440-65-5D, Yttrium, cyclen derivative
     complexes   70152-55-5D, aptamer conjugates   761411-05-6D, Rhenium,
     technetium or yttrium complexes
     RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (aptamers and cyclen compds. and complexes for detection, monitoring
        and treatment of cancer)

L10  ANSWER 19 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:565117  CAPLUS
DOCUMENT NUMBER:          141:122334
TITLE:                    Immunotherapy of B cell malignancies and autoimmune
                          disease using unconjugated and conjugated antibodies,
                          fragments or fusion proteins
INVENTOR(S):              Goldenberg, David M.; Hansen, Hans
PATENT ASSIGNEE(S):       Immunomedics, Inc., USA; Mccall, John Douglas
SOURCE:                   PCT Int. Appl., 49 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
     WO 2004058298        A1    20040715    WO 2003-GB5700         20031231 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
```

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20040219156	A1	20041104	US 2003-747199		20031230 <--
CA	2512188	A1	20040715	CA 2003-2512188		20031231 <--
AU	2003295166	A1	20040722	AU 2003-295166		20031231 <--
EP	1578440	A1	20050928	EP 2003-786167		20031231 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR	2003017898	A	20051206	BR 2003-17898		20031231 <--
CN	1756561	A	20060405	CN 2003-80110054		20031231 <--
JP	2006513203	T	20060420	JP 2004-563380		20031231 <--
RU	2335297	C2	20081010	RU 2005-124281		20031231 <--
MX	2005PA07245	A	20050912	MX 2005-PA7245		20050630 <--
IN	2005CN01727	A	20070706	IN 2005-CN1727		20050728 <--
PRIORITY APPLN. INFO.:				US 2002-437145P	P	20021231 <--
				WO 2003-GB5700	W	20031231 <--

AB The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed. The target antigen of the unconjugated and conjugated antibody is CD3, CD4, CD5, CD8, CD11c, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD74, CD80, CD126, MUC1 , tenascin, Ia, HMI.24, HLA-DR and tumor antigen. The antibody is human, murine, chimeric, primatized or humanized antibody. The antibody is conjugated with therapeutic agent selected from drug, toxin, immunomodulator, chelator, boron compound, photoactive agent or radionuclide.

TI Immunotherapy of B cell malignancies and autoimmune disease using unconjugated and conjugated antibodies, fragments or fusion proteins

PRAI	US 2002-437145P	P	20021231	<--
	WO 2003-GB5700	W	20031231	<--

AB The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed. The target antigen of the unconjugated and conjugated antibody is CD3, CD4, CD5, CD8, CD11c, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD74, CD80, CD126, MUC1 , tenascin, Ia, HMI.24, HLA-DR and tumor antigen. The antibody is human, murine, chimeric, primatized or humanized antibody. The antibody is conjugated with therapeutic agent selected from drug, toxin, immunomodulator, chelator, boron compound, photoactive agent or radionuclide.

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Heavy metals
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; unconjugated and conjugated antibodies, fragments or antibody

fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

L10 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:120888 CAPLUS
DOCUMENT NUMBER: 140:198085
TITLE: Chimeric and humanized anti-α-fetoprotein antibodies Immu31 and fragments for diagnosis and therapy of hepatocellular carcinoma, hepatoblastoma and germ cell tumors
INVENTOR(S): Hansen, Hans; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013180	A2	20040212	WO 2003-GB3325	20030801 <--
WO 2004013180	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494310	A1	20040212	CA 2003-2494310	20030801 <--
AU 2003248982	A1	20040223	AU 2003-248982	20030801 <--
US 20040235065	A1	20041125	US 2003-631722	20030801 <--
US 7300655	B2	20071127		
EP 1546203	A2	20050629	EP 2003-766456	20030801 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516086	T	20060622	JP 2004-525545	20030801 <--
IN 2005CN00297	A	20070817	IN 2005-CN297	20050301 <--
US 20080146784	A1	20080619	US 2007-870627	20071011 <--
PRIORITY APPLN. INFO.:			US 2002-399707P P	20020801 <--
			US 2003-631722 A3	20030801 <--
			WO 2003-GB3325 W	20030801 <--

AB The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors, carcinoma and other AFP-producing tumors.

TI Chimeric and humanized anti-α-fetoprotein antibodies Immu31 and fragments for diagnosis and therapy of hepatocellular carcinoma, hepatoblastoma and germ cell tumors

PRAI US 2002-399707P	P	20020801	<--
US 2003-631722	A3	20030801	<--
WO 2003-GB3325	W	20030801	<--

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; chimeric and humanized anti-α-fetoprotein

antibodies Immu31 and fragments for diagnosis and therapy of hepatocellular carcinoma, hepatoblastoma and germ cell tumors)

IT Abrins
Alkaloids, biological studies
Anthracyclines
Carbohydrates, biological studies
Carcinoembryonic antigen
Cytokines
Enterotoxin A
Enzymes, biological studies
Exotoxins
Fusion proteins (chimeric proteins)
Haptens
Hemopoietins
Hormone antagonists
Hormones, animal, biological studies
Insulin-like growth factor I receptors
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Lymphotoxin
Metals, biological studies
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins
Toxins
Tumor necrosis factors
neu (receptor)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric and humanized anti-α-fetoprotein antibodies Immu31 and fragments for diagnosis and therapy of hepatocellular carcinoma, hepatoblastoma and germ cell tumors)

L10 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1007015 CAPLUS
DOCUMENT NUMBER: 140:58438
TITLE: Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis and therapy of pancreatic cancer
INVENTOR(S): Gold, David V.; Goldenberg, David M.; Hansen, Hans
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106497	A1	20031224	WO 2003-GB2585	20030616 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2489469	A1	20031224	CA 2003-2489469	20030616	<--
AU	2003250367	A1	20031231	AU 2003-250367	20030616	<--
US	20040057902	A1	20040325	US 2003-461878	20030616	<--
US	7238786	B2	20070703			
EP	1521775	A1	20050413	EP 2003-760086	20030616	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
JP	2006507803	T	20060309	JP 2004-513328	20030616	<--
PRIORITY APPLN. INFO.:				US 2002-388313P	P 20020614	<--
				WO 2003-GB2585	W 20030616	<--

AB This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

TI Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis and therapy of pancreatic cancer

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis and therapy of pancreatic cancer

PRAI US 2002-388313P P 20020614 <--
WO 2003-GB2585 W 20030616 <--

ST chimeric monoclonal antibody PAM4 human MUC1 pancreatic cancer carcinoma

IT Interleukins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B72.3; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bcl-2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CC49; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(CSAp or colon-specific antigen p; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DUPAN2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Lea, sialyl; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Lea; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ley; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC3; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nd2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Ribosome-inactivating proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein); multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Exotoxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pseudomonas; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT PCR (polymerase chain reaction)
(RT-PCR (reverse transcription-PCR); multivalent humanized monoclonal

anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SPAN1; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Enterotoxin A
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Staphylococcal; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAG-72 (tumor-associated glycoprotein 72); multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP53; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Imaging agents
(acoustic imaging contrast agents; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Imaging agents
(acoustic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Anthracyclines
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs and derivs.; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Growth inhibitors, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiogenic growth-inhibiting factor; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-idiotypic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Cytotoxic agents
(antimetabolites; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Luminescent substances
(bioluminescent; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Endoscopes
Surgery
(cancer diagnosis; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Diagnosis

(cancer; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Pancreas, neoplasm
(carcinoma; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Drug delivery systems
(carriers; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Biology
(cell, host; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Imaging agents
(contrast; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, Pseudomonas; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Oils
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethiodized; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Liposomes
(gas-filled ultrasound enhancing agent; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Diagnosis
(genetic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Drug delivery systems
Drug delivery systems

(immunoconjugates; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Diagnosis
(immunodiagnosis; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(immunotoxins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Apoptosis
Mitosis
(inhibitors; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(liposomes, gas-filled ultrasound enhancing agent; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Pigments, biological
(luciferins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal, PAM4; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Affinity
Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Antitumor agents
Carcinoma
Chemiluminescent substances
Chemotherapy
Color formers
Cytotoxic agents
DNA sequences
Diagnostic agents
Drugs
Dyes
Epitopes
Fluorescent substances
Genetic vectors
Human
Immunohistochemistry
Immunomodulators
Immunoradiotherapy
Immunosuppressants
Immunotherapy
Labels
Molecular cloning
Mus
PCR (polymerase chain reaction)
Pancreas, neoplasm
Paramagnetic materials
Primates
Protein sequences

Protein sequences
Pseudomonas
Repeat motifs (protein)
Rodentia
Staphylococcus
Tumor markers
Yeast
cDNA sequences
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Abrins
Aequorins
Alkaloids, biological studies
Allophycocyanins
Angiogenic factors
Antigens
Antisense oligonucleotides
CA19-9 antigen
CD40 (antigen)
Carcinoembryonic antigen
Cytokines
Enzyme inhibitors
Enzymes, biological studies
Epidermal growth factor receptors
Fusion proteins (chimeric proteins)
Haptens
Hemopoietins
Hormone antagonists
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Lymphotoxin
Metals, biological studies
Mucins
Oligonucleotides
Phycocyanins
Phycoerythrins
Platelet-derived growth factors
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins
Toxins
Tumor antigens
Tumor necrosis factors
neu (receptor)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncogene; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Carcinoma
(pancreatic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(parenterals; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Chemicals
(photoactive; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Ribosome-inactivating proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporin; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Mutagenesis
(site-directed, substitution; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Animal cell
Animal tissue
Samples
(specimen; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppressant; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Animals
Embryophyta
Microorganism
Plants
(toxins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Vaccines
(tumor; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antitumor agents
(vaccines; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(γ; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 637793-17-0 637793-18-1 637793-19-2 637793-20-5 637793-21-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 9003-99-0, Peroxidase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(horseradish; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 329900-75-6, Cyclooxygenase 2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 156847-82-4 637748-42-6 637748-44-8 637748-46-0 637748-48-2 637748-50-6
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 55-86-7D, Nitrogen mustard, analogs 57-13-6D, Urea, substituted derivs. 59-05-2, Methotrexate 59-30-3D, Folic acid, analogs and derivs. 60-34-4D, Methylhydrazine, derivs. 96-83-3, Iopanoic acid 117-96-4, Diatrizoate 120-73-0D, Purine, analogs and derivs. 144-62-7D, Ethanedioic acid, salts 288-32-4, Imidazole, biological studies 289-95-2D, Pyrimidine, analogs and derivs. 440-58-4, Iodamide 521-31-3, Luminol 587-61-1, Propyliodone 606-17-7, Iodipamide 643-79-8, o-Phthalaldehyde 1456-52-6, Ioprocemic acid 1605-68-1D, Taxane, analogs and derivs. 1949-45-7, Metrizoate 2276-90-6, Iothalamic acid 3682-14-2, Isoluminol 4375-07-9, Epipodophyllotoxin 5587-89-3 5591-33-3, Iosefamic acid 6284-40-8, Meglumine 7440-06-4D, Platinum, coordination compds. 7440-28-0D, Thallium, compds. 7440-39-3D, Barium, compds. 7440-55-3D, Gallium, compds. 7553-56-2D, Iodine, compds. 7689-03-4D, Camptothecin, analogs and derivs. 7791-12-0, Thallous chloride 9000-81-1, Acetylcholineesterase 9001-05-2, Catalase 9001-37-0, Glucose oxidase 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-64-3, Malate dehydrogenase 9001-78-9, Alkaline phosphatase 9001-99-4, RNase 9002-13-5, Urease 9003-98-9, DNase I 9013-53-0, Staphylococcal nuclease 9014-00-0, Luciferase 9014-42-0, Thrombopoietin 9015-68-3, Asparaginase 9023-78-3, Triose phosphate isomerase 9031-11-2, β-Galactosidase 9031-36-1, δ-5-Steroid isomerase 9031-72-5, Alcohol dehydrogenase 9032-08-0, Glucoamylase 9075-65-4, α-Glycerophosphate dehydrogenase 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 10397-75-8, Iocarmic acid 11096-26-7, Erythropoietin 13010-20-3D, Nitrosourea, analogs and derivs. 13558-31-1 13967-65-2, Holmium-166, biological studies 13981-22-1, Nitrogen-13, biological studies 13981-25-4, Copper-64, biological studies 13981-27-6, Zirconium-89, biological studies 13981-56-1, Fluorine-18, biological studies 13982-25-7, Cobalt-55, biological studies 13982-43-9, Oxygen-15, biological studies 14093-04-0, Iron-52, biological studies 14119-09-6, Gallium-67, biological studies 14133-75-6, Indium-110, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14191-64-1, Praseodymium-142, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14280-50-3, biological studies 14333-33-6, Carbon-11, biological studies 14333-34-7, Gadolinium-155, biological studies 14378-26-8, Rhenium-188,

biological studies 14391-19-6, Terbium-161, biological studies 14391-32-3, Gadolinium-157, biological studies 14391-96-9, Scandium-47, biological studies 14392-03-1, Manganese-51, biological studies 14392-07-5, Gadolinium-156, biological studies 14596-37-3, Phosphorus-32, biological studies 14683-24-0, Gadolinium-154, biological studies 14701-22-5, Nickel(II), biological studies 14809-47-3, Bromine-75, biological studies 14809-53-1, Yttrium-86, biological studies 14809-55-3, Technetium-94, biological studies 14913-49-6, Bismuth-212, biological studies 14913-52-1, Neodymium(3+), biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, analogs and derivs. 15068-71-0, Gadolinium-158, biological studies 15092-94-1, Lead-212, biological studies 15121-26-3, Vanadium(2+), biological studies 15158-11-9, Copper(II), biological studies 15438-31-0, biological studies 15480-34-9, Iodine-120, biological studies 15623-45-7, Radium-223, biological studies 15715-08-9, Iodine-123, biological studies 15749-66-3, Phosphorus-33, biological studies 15750-15-9, Indium-111, biological studies 15755-33-6, Arsenic-72, biological studies 15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15760-04-0, Silver-111, biological studies 15765-38-5, Bromine-76, biological studies 15765-78-3, Rhenium-189, biological studies 15766-00-4, Samarium-153, biological studies 15776-20-2, Bismuth-213, biological studies 15840-01-4, Dysprosium-166, biological studies 16034-77-8, Iocetamic acid 16065-83-1, Chromium(III), biological studies 16065-91-1, Gold(III), biological studies 16096-89-2, Lanthanum(III), biological studies 16397-91-4, Manganese(II), biological studies 18472-30-5, Erbium(3+), biological studies 18923-27-8, Ytterbium(3+), biological studies 19863-06-0, Ioxotrizoic acid 20074-52-6, biological studies 22541-17-9, Samarium(3+), biological studies 22541-19-1, Gadolinium(III), biological studies 22541-20-4, Terbium(3+), biological studies 22541-21-5, Dysprosium(3+), biological studies 22541-22-6, Holmium(3+), biological studies 22541-53-3, biological studies 22559-71-3D, Acridinium, aromatic esters or salts 23214-92-8D, Doxorubicin, analogs and derivs. 23713-46-4, Bismuth(3+), biological studies 27072-45-3, Fluoresceinisothiocyanate 30403-03-3, Gallium citrate 31112-62-6, Metrizamide 31127-82-9, Iodoxamic acid 33069-62-4D, Taxol, analogs and derivs. 38183-12-9, Fluorescamine 51022-74-3, Iotroxic acid 51876-99-4, Ioseric acid 59017-64-0, Ioxaglic acid 60019-19-4, Iotetric acid 60166-93-0, Iopamidol 61912-98-9, Insulin-like growth factor 62683-29-8, Colony-stimulating factor 63534-64-5, Iosulamide meglumine 66108-95-0, Iohexol 71767-13-0, Iotasul 75037-46-6, Gelonin 75751-89-2, Iogulamide 83869-56-1, GM-CSF 86639-52-3, SN-38 95058-81-4, Gemcitabine 100286-90-6, CPT-11 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 147597-66-8D, peptide conjugates 187888-07-9, Endostatin 378782-03-7, Manganese-52m, biological studies 378784-14-6, Rubidium-82m, biological studies 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies 391267-27-9 391267-28-0 391267-29-1 637771-92-7, IMP 271 637771-93-8, IMP 277 637771-94-9, IMP 288 637771-95-0, IMP 281 637771-96-1, IMP 284
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 122111-03-9, Gemzar
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 637793-15-8 637793-16-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)
(nucleotide sequence; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

L10 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1007014 CAPLUS
DOCUMENT NUMBER: 140:58437
TITLE: Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer
INVENTOR(S): Goldenberg, David M.; Hansen, Hans; Qu, Zhengxing
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2003106495	A2	20031224	WO 2003-GB2593	20030616	<--
WO 2003106495	A3	20040401			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2489467	A1	20031224	CA 2003-2489467	20030616	<--
AU 2003277087	A1	20031231	AU 2003-277087	20030616	<--
AU 2003277087	B2	20080731			
US 20050014207	A1	20050120	US 2003-461885	20030616	<--
US 7282567	B2	20071016			
EP 1519958	A2	20050406	EP 2003-740743	20030616	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011799	A	20050510	BR 2003-11799	20030616	<--
CN 1675245	A	20050928	CN 2003-819294	20030616	<--
JP 2006513695	T	20060427	JP 2004-513326	20030616	<--
MX 2004PA12656	A	20050815	MX 2004-PA12656	20041214	<--
US 20080050311	A1	20080228	US 2007-849791	20070904	<--
AU 2008212083	A1	20081002	AU 2008-212083	20080910	<--

PRIORITY APPLN. INFO.:			
	US 2002-388314P	P	20020614 <--
	AU 2003-277087	A3	20030616 <--
	US 2003-461885	A3	20030616 <--
	WO 2003-GB2593	W	20030616 <--

AB This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in

diagnosis and therapy.

TI Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer

TI Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer

PRAI US 2002-388314P P 20020614 <--
AU 2003-277087 A3 20030616 <--
US 2003-461885 A3 20030616 <--
WO 2003-GB2593 W 20030616 <--

ST multivalent humanized monoclonal antibody MUC1 cancer diagnosis therapy

IT Interleukins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B72.3; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bcl-2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CC49; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CSAp or colon-specific antigen p; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DUPAN2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Lea, sialyl; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Lea; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ley; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC3; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nd2; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Ribosome-inactivating proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein); multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Exotoxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pseudomonas; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT PCR (polymerase chain reaction)
(RT-PCR (reverse transcription-PCR); multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SPAN1; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Enterotoxin A
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Staphylococcal; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Tumor antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAG-72 (tumor-associated glycoprotein 72); multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP53; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Imaging agents
(acoustic imaging contrast agents; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Imaging agents
(acoustic; multivalent humanized monoclonal anti-MUC1

antibody PAM4 for diagnosis and treatment of cancer)
IT Anthracyclines
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs and derivs.; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-idiotypic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Cytotoxic agents
(antimetabolites; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Luminescent substances
(bioluminescent; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Endoscopes
Surgery
(cancer diagnosis; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Diagnosis
(cancer; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Pancreas, neoplasm
(carcinoma; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(carriers; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Biology
(cell, host; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Imaging agents
(contrast; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, Pseudomonas; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Oils
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethiodized; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion products; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Liposomes
(gas-filled ultrasound enhancing agent; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Diagnosis
(genetic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(immunoconjugates; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Diagnosis
(immunodiagnosis; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Drug delivery systems
(immunotoxins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Apoptosis
Mitosis
(inhibitors; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Pigments, biological
(luciferins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal, PAM4; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)
IT Affinity
Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Antitumor agents
Carcinoma
Chemiluminescent substances
Chemotherapy
Color formers

Cytotoxic agents
DNA sequences
Diagnostic agents
Drugs
Dyes
Epitopes
Fluorescent substances
Genetic vectors
Human
Immunohistochemistry
Immunomodulators
Immunoradiotherapy
Immunosuppressants
Immunotherapy
Labels
Molecular cloning
Mus
PCR (polymerase chain reaction)
Pancreas, neoplasm
Paramagnetic materials
Primates
Protein sequences
Pseudomonas
Repeat motifs (protein)
Rodentia
Staphylococcus
Tumor markers
Yeast
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Abrins
Aequorins
Alkaloids, biological studies
Allophycocyanins
Angiogenic factors
Antigens
Antisense oligonucleotides
CA19-9 antigen
CD40 (antigen)
Carcinoembryonic antigen
Cytokines
Enzyme inhibitors
Enzymes, biological studies
Epidermal growth factor receptors
Fusion proteins (chimeric proteins)
Haptens
Hemopoietins
Hormone antagonists
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Lymphotoxin
Metals, biological studies
Mucins
Oligonucleotides

Phycocyanins
Phycoerythrins
Platelet-derived growth factors
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins
Toxins
Tumor antigens
Tumor necrosis factors
neu (receptor)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncogene; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Carcinoma
(pancreatic; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Drug delivery systems
(parenterals; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Chemicals
(photoactive; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Ribosome-inactivating proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporin; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Mutagenesis
(site-directed, substitution; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Animal cell
Animal tissue
Samples
(specimen; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppressant; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Animals
Embryophyta
Microorganism
Plants
(toxins; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Vaccines
(tumor; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Antitumor agents
(vaccines; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vinca; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; multivalent humanized monoclonal anti- MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 637785-73-0P 637785-74-1P 637785-75-2P 637785-76-3P 637785-77-4P 637785-78-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 9003-99-0, Peroxidase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(horseradish; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 329900-75-6, Cyclooxygenase 2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 156847-82-4 637748-42-6 637748-44-8 637748-46-0 637748-48-2 637748-50-6
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 55-86-7D, Nitrogen mustard, analogs 57-13-6D, Urea, substituted derivs. 59-05-2, Methotrexate 59-30-3D, Folic acid, analogs and derivs. 60-34-4D, Methylhydrazine, derivs. 96-83-3, Iopanoic acid 117-96-4, Diatrizoate 120-73-0D, Purine, analogs and derivs. 144-62-7D, Ethanedioic acid, salts 288-32-4, Imidazole, biological studies 289-95-2D, Pyrimidine, analogs and derivs. 440-58-4, Iodamide 521-31-3, Luminol 587-61-1, Propyliodone 606-17-7, Iodipamide 643-79-8, o-Phthalaldehyde 1456-52-6, Ioprocemic acid 1605-68-1D, Taxane, analogs and derivs. 1949-45-7, Metrizoate 2276-90-6, Iothalamic acid 3682-14-2, Isoluminol 4375-07-9, Epipodophyllotoxin 5587-89-3 5591-33-3, Iosefamic acid 6284-40-8, Meglumine 7440-06-4D, Platinum, coordination compds. 7440-28-0D, Thallium, compds. 7440-39-3D, Barium, compds. 7440-55-3D, Gallium, compds. 7553-56-2D, Iodine, compds. 7689-03-4D, Camptothecin, analogs and derivs. 7791-12-0, Thallous chloride 9000-81-1, Acetylcholineesterase 9001-05-2, Catalase 9001-37-0, Glucose oxidase 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-64-3, Malate dehydrogenase

9001-78-9, Alkaline phosphatase 9001-99-4, RNase 9002-13-5, Urease
9003-98-9, DNase I 9014-00-0, Luciferase 9014-42-0, Thrombopoietin
9015-68-3, Asparaginase 9023-78-3, Triose phosphate isomerase
9031-11-2, β-Galactosidase 9031-36-1, Δ5-Steroid isomerase
9031-72-5, Alcohol dehydrogenase 9032-08-0, Glucoamylase 9075-65-4,
α-Glycerophosphate dehydrogenase 10043-66-0, Iodine-131,
biological studies 10098-91-6, Yttrium-90, biological studies
10397-75-8, Iocarmic acid 11096-26-7, Erythropoietin 13010-20-3D,
Nitrosourea, analogs and derivs. 13558-31-1 13967-65-2, Holmium-166,
biological studies 13981-22-1, Nitrogen-13, biological studies
13981-25-4, Copper-64, biological studies 13981-27-6, Zirconium-89,
biological studies 13981-56-1, Fluorine-18, biological studies
13982-25-7, Cobalt-55, biological studies 13982-43-9, Oxygen-15,
biological studies 14093-04-0, Iron-52, biological studies 14119-09-6,
Gallium-67, biological studies 14133-75-6, Indium-110, biological
studies 14158-30-6, Iodine-124, biological studies 14158-31-7,
Iodine-125, biological studies 14191-64-1, Praseodymium-142, biological
studies 14265-75-9, Lutetium-177, biological studies 14265-85-1,
Actinium-225, biological studies 14276-53-0, Copper-62, biological
studies 14280-50-3, biological studies 14333-33-6, Carbon-11,
biological studies 14333-34-7, Gadolinium-155, biological studies
14378-26-8, Rhenium-188, biological studies 14391-19-6, Terbium-161,
biological studies 14391-32-3, Gadolinium-157, biological studies
14391-96-9, Scandium-47, biological studies 14392-03-1, Manganese-51,
biological studies 14392-07-5, Gadolinium-156, biological studies
14596-37-3, Phosphorus-32, biological studies 14683-24-0,
Gadolinium-154, biological studies 14701-22-5, Nickel(II), biological
studies 14809-47-3, Bromine-75, biological studies 14809-53-1,
Yttrium-86, biological studies 14809-55-3, Technetium-94, biological
studies 14913-49-6, Bismuth-212, biological studies 14913-52-1,
Neodymium(3+), biological studies 14998-63-1, Rhenium-186, biological
studies 15056-34-5D, Triazene, analogs and derivs. 15068-71-0,
Gadolinium-158, biological studies 15092-94-1, Lead-212, biological
studies 15121-26-3, Vanadium(2+), biological studies 15158-11-9,
Copper(II), biological studies 15438-31-0, biological studies
15480-34-9, Iodine-120, biological studies 15623-45-7, Radium-223,
biological studies 15715-08-9, Iodine-123, biological studies
15749-66-3, Phosphorus-33, biological studies 15750-15-9, Indium-111,
biological studies 15755-33-6, Arsenic-72, biological studies
15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68,
biological studies 15757-86-5, Copper-67, biological studies
15760-04-0, Silver-111, biological studies 15765-38-5, Bromine-76,
biological studies 15765-78-3, Rhenium-189, biological studies
15766-00-4, Samarium-153, biological studies 15776-20-2, Bismuth-213,
biological studies 15840-01-4, Dysprosium-166, biological studies
16034-77-8, Iocetamic acid 16065-83-1, Chromium(III), biological studies
16065-91-1, Gold(III), biological studies 16096-89-2, Lanthanum(III),
biological studies 16397-91-4, Manganese(II), biological studies
18472-30-5, Erbium(3+), biological studies 18923-27-8, Ytterbium(3+),
biological studies 19863-06-0, Ioxotrizoic acid 20074-52-6, biological
studies 22541-17-9, Samarium(3+), biological studies 22541-19-1,
Gadolinium(III), biological studies 22541-20-4, Terbium(3+), biological
studies 22541-21-5, Dysprosium(3+), biological studies 22541-22-6,
Holmium(3+), biological studies 22541-53-3, biological studies
22559-71-3D, Acridinium, aromatic esters 22559-71-3D, Acridinium, salts
23214-92-8D, Doxorubicin, analogs and derivs. 23713-46-4, biological
studies 27072-45-3, Fluoresceinisothiocyanate 30403-03-3, Gallium
citrate 31112-62-6, Metrizamide 31127-82-9, Iodoxamic acid
33069-62-4D, Taxol, analogs and derivs. 38183-12-9, Fluorescamine
51022-74-3, Iotroxic acid 51876-99-4, Ioseric acid 59017-64-0,
Ioxaglic acid 60019-19-4, Iotetric acid 60166-93-0, Iopamidol
61912-98-9, Insulin-like growth factor 62683-29-8, Colony-stimulating

factor 63534-64-5, Iosulamide meglumine 66108-95-0, Iohexol 71767-13-0, Iotasul 75037-46-6, Gelonin 75751-89-2, Iogulamide 83869-56-1, GM-CSF 86639-52-3, SN-38 95058-81-4, Gemcitabine 100286-90-6, CPT-11 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 187888-07-9, Endostatin 378782-03-7, Manganese-52m, biological studies 378784-14-6, Rubidium-82m, biological studies 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies 391267-27-9 391267-28-0 391267-29-1 637771-92-7, IMP 271 637771-93-8, IMP 277 637771-94-9, IMP 288 637771-95-0, IMP 281 637771-96-1, IMP 284
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 122111-03-9, Gemzar
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 637782-59-3P 637785-70-7P 637785-71-8P 637785-72-9P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 9026-81-7, Nuclease
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(staphylococcal; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

IT 637785-96-7 637785-97-8 637785-98-9 637785-99-0 637786-00-6 637786-01-7 637786-02-8 637786-03-9 637786-04-0 637786-05-1 637786-06-2 637786-07-3
RL: PRP (Properties)
(unclaimed sequence; multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer)

L10 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:972220 CAPLUS
DOCUMENT NUMBER: 140:24702
TITLE: Use of self-associating peptides derived from a membrane translocating sequence to direct aggregation
INVENTOR(S): Koentgen, Frank
PATENT ASSIGNEE(S): Scegen Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 219 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003102187	A1	20031211	WO 2003-AU667	20030530 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003229392 A1 20031219 AU 2003-229392 20030530 <--
US 20040029179 A1 20040212 US 2003-449831 20030530 <--
EP 1511846 A1 20050309 EP 2003-722087 20030530 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1665931 A 20050907 CN 2003-815763 20030530 <--
JP 2005528107 T 20050922 JP 2004-510425 20030530 <--
PRIORITY APPLN. INFO.: US 2002-384878P P 20020531 <--
US 2002-384878 P 20020531 <--
WO 2003-AU667 W 20030530 <--

OTHER SOURCE(S): MARPAT 140:24702

AB A method of building multi-subunit complexes of proteins, e.g. to improve the activity of a mol., or to combine individual activities of different mols., using peptides derived from self-coalescing elements to direct the formation of aggregates is described. The present invention also discloses such chimeric mols. per se and their use in therapeutic, prophylactic and chemical process applications. In particular, methods of inducing complex formation in the activation of B cells are described. The self-coalescing elements are derived from the membrane translocation sequences of of secreted proteins.

TI Use of self-associating peptides derived from a membrane translocating sequence to direct aggregation

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI US 2002-384878P P 20020531 <--
US 2002-384878 P 20020531 <--
WO 2003-AU667 W 20030530 <--

IT Mucins
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(MUC1, fusion products with self-coalescing elements; use of self-associating peptides derived from membrane translocating sequence to direct aggregation)

IT Proteins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metal-binding, complexes containing, induction of aggregation of; use of self-associating peptides derived from membrane translocating sequence to direct aggregation)

L10 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:836381 CAPLUS
DOCUMENT NUMBER: 139:341719
TITLE: Use of bi-specific antibodies for pre-targeting diagnosis and therapy
INVENTOR(S): Goldenberg, David M.; Hansen, Hans J.; Leung, Shui-on; McBride, William J.; Qu, Zhengxing
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 823,746.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030198595	A1	20031023	US 2002-150654	20020517 <--
US 7138103	B2	20061121		

US 7074405	B1	20060711	US 1999-337756	19990622	<--
US 7052872	B1	20060530	US 1999-382186	19990823	<--
US 20020006379	A1	20020117	US 2001-823746	20010403	<--
US 6962702	B2	20051108			
CA 2486307	A1	20031127	CA 2003-2486307	20030516	<--
WO 2003097105	A1	20031127	WO 2003-GB2110	20030516	<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003227939	A1	20031202	AU 2003-227939	20030516	<--
AU 2003227939	B2	20071129			
EP 1506018	A1	20050216	EP 2003-725404	20030516	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003010088	A	20050405	BR 2003-10088	20030516	<--
CN 1668335	A	20050914	CN 2003-816898	20030516	<--
JP 2006506325	T	20060223	JP 2004-505100	20030516	<--
US 20050002945	A1	20050106	US 2004-776470	20040211	<--
US 7405320	B2	20080729			
MX 2004PA11422	A	20050217	MX 2004-PA11422	20041117	<--
IN 2004CN02815	A	20060210	IN 2004-CN2815	20041213	<--
US 20060034759	A1	20060216	US 2005-198846	20050808	<--
US 20060140858	A1	20060629	US 2005-514632	20050912	<--
US 20070048227	A1	20070301	US 2006-553814	20061027	<--

PRIORITY APPLN. INFO.:		US 1998-90142P	P	19980622 <--
		US 1998-104156P	P	19981014 <--
		US 1999-337756	A	19990622 <--
		US 1999-382186	A2	19990823 <--
		US 2001-823746	A2	20010403 <--
		US 2002-150654	A	20020517 <--
		US 2002-426379P	P	20021115 <--
		WO 2003-GB2110	W	20030516 <--
		US 2003-714391	A2	20031117 <--
		US 2005-198846	A2	20050808

AB The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

TI Use of bi-specific antibodies for pre-targeting diagnosis and therapy

REFERENCE COUNT: 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PRAI US 1998-90142P	P	19980622	<--
US 1998-104156P	P	19981014	<--
US 1999-337756	A	19990622	<--
US 1999-382186	A2	19990823	<--
US 2001-823746	A2	20010403	<--
US 2002-150654	A	20020517	<--
US 2002-426379P	P	20021115	<--
WO 2003-GB2110	W	20030516	<--

US 2003-714391 A2 20031117 <--
US 2005-198846 A2 20050808
IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; bi-specific antibodies for pre-targeting diagnosis and therapy)
IT Actinides
Alkali metals, biological studies
Group IIIA elements
Rare earth metals, biological studies
Transition metals, biological studies
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bi-specific antibodies for pre-targeting diagnosis and therapy)

L10 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:719518 CAPLUS
DOCUMENT NUMBER: 139:259962
TITLE: Humanized murine anti-epithelial glycoprotein 1 (EGP-1) antibodies RS7 and conjugates for diagnosis and treatment of cancer
INVENTOR(S): Govindan, Serengulam; Qu, Zhengxing; Hansen, Hans J.; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; Mccall, John Douglas
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074566	A2	20030912	WO 2003-GB885	20030303 <--
WO 2003074566	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478047	A1	20030912	CA 2003-2478047	20030303 <--
AU 2003209447	A1	20030916	AU 2003-209447	20030303 <--
AU 2003209447	B2	20080918		
US 20040001825	A1	20040101	US 2003-377121	20030303 <--
US 7238785	B2	20070703		
EP 1483295	A2	20041208	EP 2003-743420	20030303 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1649903	A	20050803	CN 2003-809918	20030303 <--
CN 100360567	C	20080109		
JP 2006502698	T	20060126	JP 2003-573031	20030303 <--
CN 101264325	A	20080917	CN 2007-10185161	20030303 <--
US 20070212350	A1	20070913	US 2007-745896	20070508 <--
US 20080131363	A1	20080605	US 2007-868290	20071005 <--
PRIORITY APPLN. INFO.:			US 2002-360229P P	20020301 <--
			CN 2003-809918 A3	20030303 <--
			US 2003-377121 A3	20030303 <--

WO 2003-GB885 W 20030303 <--
US 2007-745896 A3 20070508

AB This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

TI Humanized murine anti-epithelial glycoprotein 1 (EGP-1) antibodies RS7 and conjugates for diagnosis and treatment of cancer

PRAI US 2002-360229P P 20020301 <--
CN 2003-809918 A3 20030303 <--
US 2003-377121 A3 20030303 <--
WO 2003-GB885 W 20030303 <--
US 2007-745896 A3 20070508

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; humanized murine anti-EGP-1 antibodies RS7 and conjugates for diagnosis and treatment of cancer)

IT Abrins
Aequorins
Alkaloids, biological studies
Allophycocyanins
Anthracyclines
Carcinoembryonic antigen
Cytokines
Enzymes, biological studies
Epidermal growth factor receptors
Ferritins
Haptens
Hemopoietins
Histones
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Keratins
Lymphotoxin
Metals, biological studies
Nucleic acids
Phycocyanins
Phycoerythrins
Prostate-specific antigen
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins

Toxins
Tumor necrosis factors
Vascular endothelial growth factor receptors
neu (receptor)
α-Fetoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized murine anti-EGP-1 antibodies RS7 and conjugates for diagnosis and treatment of cancer)

L10 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:656808 CAPLUS
DOCUMENT NUMBER: 139:196278
TITLE: Anti-CD20 antibodies and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases
INVENTOR(S): Hansen, Hans; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2003068821	A2	20030821	WO 2003-GB665	20030214	<--
WO 2003068821	A3	20050120			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2476166	A1	20030821	CA 2003-2476166	20030214	<--
AU 2003208415	A1	20030904	AU 2003-208415	20030214	<--
US 20030219433	A1	20031127	US 2003-366709	20030214	<--
US 7151164	B2	20061219			
EP 1519959	A2	20050406	EP 2003-706703	20030214	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1662557	A	20050831	CN 2003-808357	20030214	<--
JP 2006500904	T	20060112	JP 2003-567947	20030214	<--
IN 2004CN02017	A	20060224	IN 2004-CN2017	20040909	<--
US 20070020259	A1	20070125	US 2006-534103	20060921	<--
US 7435803	B2	20081014			
IN 2007CN03444	A	20071116	IN 2007-CN3444	20070806	<--
IN 2007CN03585	A	20080627	IN 2007-CN3585	20070816	<--

PRIORITY APPLN. INFO.:		US 2002-356132P	P	20020214 <--
		US 2002-416232P	P	20021007 <--
		US 2003-366709	A1	20030214 <--
		WO 2003-GB665	W	20030214 <--
		IN 2004-CN2017	A3	20040909 <--

AB The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune

diseases, and methods of treatment and diagnosis.

TI Anti-CD20 antibodies and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases

PRAI	US 2002-356132P	P	20020214	<--
	US 2002-416232P	P	20021007	<--
	US 2003-366709	A1	20030214	<--
	WO 2003-GB665	W	20030214	<--
	IN 2004-CN2017	A3	20040909	<--

IT Mucins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MUC1; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Metals, biological studies

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-radioactive; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

L10 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2003:320021 CAPLUS
DOCUMENT NUMBER:	138:336427
TITLE:	Direct targeting binding multivalent monospecific proteins of human
INVENTOR(S):	Rossi, Edmund; Chang, Chien-Hsing Ken; Goldenberg, David M.
PATENT ASSIGNEE(S):	IBC Pharmaceuticals, USA; Immunomedics Inc.
SOURCE:	PCT Int. Appl., 62 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033654	A2	20030424	WO 2002-US32718	20021015 <--
WO 2003033654	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463672	A1	20030424	CA 2002-2463672	20021015 <--
AU 2002348437	A1	20030428	AU 2002-348437	20021015 <--
US 20030148409	A1	20030807	US 2002-270073	20021015 <--
EP 1448780	A2	20040825	EP 2002-782156	20021015 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005507659	T	20050324	JP 2003-536384	20021015 <--
CN 1604966	A	20050406	CN 2002-825068	20021015 <--
BR 2002013303	A	20050607	BR 2002-13303	20021015 <--
MX 2004PA03535	A	20050620	MX 2004-PA3535	20040415 <--
IN 2004CN01047	A	20060203	IN 2004-CN1047	20040513 <--
PRIORITY APPLN. INFO.:			US 2001-328835P P	20011015 <--

```
                                        US 2001-341881P     P  20011221 <--
                                        US 2002-345641P     P  20020108 <--
                                        US 2002-404919P     P  20020822 <--
                                        WO 2002-US32718     W  20021015 <--
AB   The present invention relates to multivalent, monospecific binding
     proteins.  These binding proteins comprise two or more binding sites,
     where each binding site specifically binds to the same type of target
     cell, and preferably with the same antigen on such a target cell.  The
     present invention further relates to compns. of monospecific diabodies,
     triabodies, and tetrabodies, and to recombinant vectors useful for the
     expression of these functional binding proteins in a microbial host.  Also
     provided are methods of using invention compns. in the treatment and/or
     diagnosis of tumors.
TI   Direct targeting binding multivalent monospecific proteins of human
PRAI US 2001-328835P      P     20011015  <--
     US 2001-341881P      P     20011221  <--
     US 2002-345641P      P     20020108  <--
     US 2002-404919P      P     20020822  <--
     WO 2002-US32718      W     20021015  <--
IT   Mucins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (MUC1; direct targeting binding multivalent monospecific
        proteins of human)
IT   Abrins
     Anthracyclines
     Carcinoembryonic antigen
     Cytokines
     Enzymes, biological studies
     Epidermal growth factor receptors
     Growth factors, animal
     Hemopoietins
     Hormones, animal, biological studies
     Lymphotoxin
       Metals, biological studies
     Prostate-specific antigen
     Ricins
     Taxanes
     Tenascins
     Toxins
     Tumor necrosis factors
     RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (direct targeting binding multivalent monospecific proteins of human)

L10  ANSWER 28 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2002:657918  CAPLUS
DOCUMENT NUMBER:          137:200246
TITLE:                    Preparation of tumor antigen-specific cytotoxic T
                          lymphocytes for cancer therapy
INVENTOR(S):              Degraw, Juli; Moriarty, Ann; Leturcq, Didier J.;
                          Jackson, Michael R.; Peterson, Per A.; Heiskala, Marja
PATENT ASSIGNEE(S):       Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE:                   PCT Int. Appl., 99 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2002065992        A2    20020829    WO 2002-US5748         20020219 <--
```

```
     WO 2002065992        A3    20030213
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2438754           A1    20020829    CA 2002-2438754          20020219 <--
     AU 2002306587        A1    20020904    AU 2002-306587           20020219 <--
     EP 1377251           A2    20040107    EP 2002-742493           20020219 <--
     EP 1377251           B1    20080528
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     BR 2002007399        A     20041026    BR 2002-7399             20020219 <--
     CN 1571834           A     20050126    CN 2002-808296           20020219 <--
     HU 2004002656        A2    20050329    HU 2004-2656             20020219 <--
     JP 2006510567        T     20060330    JP 2002-565553           20020219 <--
     NZ 527683            A     20060630    NZ 2002-527683           20020219 <--
     AT 396691            T     20080615    AT 2002-742493           20020219 <--
     NO 2003003674        A     20031017    NO 2003-3674             20030819 <--
     MX 2003PA07503       A     20041015    MX 2003-PA7503           20030820 <--
     ZA 2003007327        A     20050113    ZA 2003-7327             20030918 <--
     JP 2005139118        A     20050602    JP 2003-377653           20031107 <--
     AU 2008200524        A1    20080221    AU 2008-200524           20080205 <--
PRIORITY APPLN. INFO.:                       US 2001-270252P      P  20010220 <--
                                             AU 2002-306587       A3 20020219 <--
                                             WO 2002-US5748       W  20020219 <--
```

AB T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naive cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen-presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory mols., are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I mols. expressed to a high d. on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.

TI Preparation of tumor antigen-specific cytotoxic T lymphocytes for cancer therapy

```
PRAI US 2001-270252P      P     20010220  <--
     AU 2002-306587       A3    20020219  <--
     WO 2002-US5748       W     20020219  <--
```

IT Mucins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; preparation of tumor antigen-specific cytotoxic T lymphocytes for cancer therapy)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metal response consensus sequence; preparation of tumor antigen-specific cytotoxic T lymphocytes for cancer therapy)

```
L10  ANSWER 29 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:          2000:277876  CAPLUS
```

DOCUMENT NUMBER: 132:313678
TITLE: Metal salt particle-adsorbed adjuvant systems and vaccines
INVENTOR(S): Garcon, Nathalie
PATENT ASSIGNEE(S): Smithkline Beecham Biologicals SA, Belg.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023105	A2	20000427	WO 1999-EP7764	19991008 <--
WO 2000023105	A3	20000803		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347099	A1	20000427	CA 1999-2347099	19991008 <--
AU 2000011518	A	20000508	AU 2000-11518	19991008 <--
AU 750587	B2	20020725		
BR 9915545	A	20010814	BR 1999-15545	19991008 <--
EP 1126876	A2	20010829	EP 1999-970607	19991008 <--
EP 1126876	B1	20070321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200101055	T2	20010921	TR 2001-1055	19991008 <--
NZ 511113	A	20020927	NZ 1999-511113	19991008 <--
HU 2002003091	A2	20021228	HU 2002-3091	19991008 <--
HU 2002003091	A3	20080428		
JP 2003519084	T	20030617	JP 2000-576878	19991008 <--
CN 1572324	A	20050202	CN 2004-10069442	19991008 <--
EP 1588714	A2	20051026	EP 2005-76368	19991008 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY				
EP 1666060	A1	20060607	EP 2005-77501	19991008 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY				
AT 357252	T	20070415	AT 1999-970607	19991008 <--
EP 1797896	A1	20070620	EP 2007-100777	19991008 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI				
ES 2284287	T3	20071101	ES 1999-970607	19991008 <--
TW 586936	B	20040511	TW 1999-88117873	19991015 <--
NO 2001001801	A	20010530	NO 2001-1801	20010409 <--
ZA 2001002954	A	20020520	ZA 2001-2954	20010410 <--
MX 2001PA03737	A	20010731	MX 2001-PA3737	20010411 <--
IN 2001CN00517	A	20050304	IN 2001-CN517	20010411 <--
US 7357936	B1	20080415	US 2001-807657	20010416 <--
HK 1038695	A1	20070914	HK 2002-100151	20020109 <--
JP 2007262097	A	20071011	JP 2007-187001	20070718 <--
IN 2007CN03642	A	20080627	IN 2007-CN3642	20070821 <--
US 20080226672	A1	20080918	US 2008-945493	20080228 <--
PRIORITY APPLN. INFO.:			GB 1998-22703 A	19981016 <--
			GB 1998-22709 A	19981016 <--
			GB 1998-22712 A	19981016 <--

EP 1999-970607	A3	19991008	<--
JP 2000-576878	A3	19991008	<--
WO 1999-EP7764	W	19991008	<--
IN 2001-CN517	A3	20010411	<--
US 2001-807657	A1	20010416	<--

AB The present invention provides vaccine and adjuvant formulations comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed onto a particle of metal salt (e.g. aluminum hydroxide or phosphate) and the resulting particle is essentially devoid of antigen.

TI Metal salt particle-adsorbed adjuvant systems and vaccines

TI Metal salt particle-adsorbed adjuvant systems and vaccines

PRAI	GB 1998-22703	A	19981016	<--
	GB 1998-22709	A	19981016	<--
	GB 1998-22712	A	19981016	<--
	EP 1999-970607	A3	19991008	<--
	JP 2000-576878	A3	19991008	<--
	WO 1999-EP7764	W	19991008	<--
	IN 2001-CN517	A3	20010411	<--
	US 2001-807657	A1	20010416	<--

AB The present invention provides vaccine and adjuvant formulations comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed onto a particle of metal salt (e.g. aluminum hydroxide or phosphate) and the resulting particle is essentially devoid of antigen.

ST metal salt adsorbent adjuvant vaccine

IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(17-1A; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(BAGE; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Melanoma-associated antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CAGE; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Genetic element
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CpG island, oligonucleotides containing; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Immunoglobulins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(E, antigens of; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(LnRH; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Melanoma-associated antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(MAGE (melanoma-associated antigen-encoding gene); metal salt particle-adsorbed adjuvant systems and vaccines)

IT Mucins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(MUC1; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(PRAME (preferentially expressed antigen of nelanoma); metal salt particle-adsorbed adjuvant systems and vaccines)

IT Immunostimulants
(adjuvants; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Bordetella
Borrelia
Chlamydia
Dengue virus
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis E virus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 5
Human immunodeficiency virus
Human papillomavirus
Influenza virus
Melanoma
Neisseria
Plasmodium (malarial genus)
Pollen
Respiratory syncytial virus
Salmonella
Toxoplasma
(antigens of; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Meningitis
(aseptic, antigens of; metal salt particle-adsorbed adjuvant systems and vaccines)

IT Allergy inhibitors
Antibacterial agents
Antiviral agents
Immunization
Immunostimulants
Parasiticides

Vaccines
(metal salt particle-adsorbed adjuvant systems and vaccines)
IT Carcinoembryonic antigen
Prostate-specific antigen
neu (receptor)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(metal salt particle-adsorbed adjuvant systems and vaccines)
IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(metal salt particle-adsorbed adjuvant systems and vaccines)
IT Hydroxides (inorganic)
Phosphates, biological studies
Salts, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(metal salt particle-adsorbed adjuvant systems and vaccines)
IT Lipid A
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(monophosphates, 3-O-deacylated; metal salt particle-adsorbed adjuvant systems and vaccines)
IT Lipid A
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(monophosphates; metal salt particle-adsorbed adjuvant systems and vaccines)
IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(tumor-associated; metal salt particle-adsorbed adjuvant systems and vaccines)
IT Vaccines
(tumor; metal salt particle-adsorbed adjuvant systems and vaccines)
IT Antitumor agents
(vaccines; metal salt particle-adsorbed adjuvant systems and vaccines)
IT 141256-04-4, QS21
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(metal salt particle-adsorbed adjuvant systems and vaccines)
IT 7429-90-5D, Aluminum, salts, biological studies 7439-89-6D, Iron, salts, biological studies 7440-41-7D, Beryllium, salts, biological studies 7440-45-1D, Cerium, salts, biological studies 7440-47-3D, Chromium, salts, biological studies 7440-66-6D, Zinc, salts, biological studies 7440-70-2D, Calcium, salts, biological studies 7784-30-7, Aluminum phosphate 21645-51-2, Aluminum hydroxide, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(metal salt particle-adsorbed adjuvant systems and vaccines)

=> fil stnguide
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	176.52	177.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-28.80	-28.80

FILE 'STNGUIDE' ENTERED AT 16:02:32 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 14, 2008 (20081114/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	177.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-28.80

STN INTERNATIONAL LOGOFF AT 16:02:40 ON 17 NOV 2008